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ABSTRACT
Macrophages Loaded with Gold Nanoshells
for Photothermal Ablation of Glioma:
an In Vitro Model
by
Amani Riad Makkouk
Dr. Steen Madsen, Examination Committee Chair
Associate Professor of Health Physics
University of Nevada, Las Vegas
The current median survival of patients with glioblastoma multiforme (GBM), the
most common type of glioma, remains at 14.6 months despite multimodal treatments
(surgery, radiotherapy and chemotherapy). This research aims to study the feasibility of
photothermal ablation of glioma using gold nanoshells that are heated upon laser
irradiation at their resonance wavelength. The novelty of our approach lies in improving
nanoshell tumor delivery by loading them in macrophages, which are known to be
recruited to gliomas via tumor-released chemoattractive agents. Ferumoxides,
superparamagnetic iron oxide (SPIO) nanoparticles, are needed as an additional
macrophage load in order to visualize macrophage accumulation in the tumor with
magnetic resonance imaging (MRI) prior to laser irradiation. The feasibility of this
approach was studied in an in vitro model of glioma spheroids with the use of continuous
wave (CW) laser light for ablation.
The optimal loading of both murine and rat macrophages with Ferumoxides was
determined using inductively coupled plasma atomic emission spectroscopy (ICP-AES).
Higher concentrations of SPIO were observed in rat macrophages, and the optimal
concentration was chosen at 100 μg Fe/ml. Macrophages were found to be very sensitive
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to near infra-red (NIR) laser irradiation, and their use as vehicles was thus not expected to
hinder the function of loaded nanoshells as tumor-ablating tools.
The intracellular presence of gold nanoshells in macrophages was confirmed with
TEM imaging. Next, the loading of both murine and rat macrophages with gold
nanoshells was studied using UV/Vis spectrophotometry, where higher nanoshell uptake
was found in rat macrophages.
Incubation of loaded murine and rat macrophages with rat C-6 and human ACBT
spheroids, respectively, resulted in their infiltration of the spheroids. Subsequent laser
irradiation at 55 W/cm2 for 10 min and follow-up of spheroid average diameter size over
14 days post-irradiation showed that ACBT, but not C-6, spheroids responded to laseractivated nanoshell therapy starting from Day 12. The lack of C-6 response was attributed
primarily to the lower nanoshell loading of murine macrophages.
Finally, the attempt to double-load macrophages with both Ferumoxides and
nanoshells failed under both simultaneous and sequential co-incubation. However, in
vivo tracking of nanoshell-loaded macrophages with Ferumoxide is likely feasible using
injections containing a mixture of Ferumoxide-loaded and nanoshell-loaded
macrophages. Overall, the proof-of-principle studies suggest that photothermal ablation
of gliomas via macrophage-mediated delivery of nanoparticles is a promising approach
and the work described herein establishes the guidelines and experimental parameters for
subsequent in vivo trial.

iv

TABLE OF CONTENTS
ABSTRACT....................................................................................................................... iii
LIST OF FIGURES ........................................................................................................... vi
ACKNOWLEDGEMENTS .............................................................................................. vii
CHAPTER 1
INTRODUCTION .................................................................................. 1
Nanoparticles ................................................................................................................ 1
Glioblastoma Multiforme (GBM) ............................................................................... 25
Macrophages ............................................................................................................... 45
Use of Macrophages Loaded with Gold Nanoshells and SPIO for GBM .................. 51
Scope of Study ............................................................................................................ 52
CHAPTER 2
MATERIALS AND METHODS .......................................................... 55
Cell Lines .................................................................................................................... 55
Nanoparticles .............................................................................................................. 56
Ferumoxides ................................................................................................................ 57
NIR Laser Irradiation of Macrophages in Absence of Nanoshells ............................. 58
Gold Nanoshells .......................................................................................................... 59
Spheroids and Macrophages ....................................................................................... 65
Double-loading of Macrophages: Nanoshells and Ferumoxides ................................ 69
Statistical Analysis ...................................................................................................... 70
CHAPTER 3 RESULTS ............................................................................................... 72
Ferumoxides Can Be Visualized Clearly ex vivo Using MRI .................................... 72
Uptake of Ferumoxides in Macrophages is Dose-Dependent..................................... 72
Macrophages Are Highly Sensitive to NIR Laser Irradiation .................................... 75
Nanoshells Are Endocytosed Into Vacuoles Dispersed Throughout The Cytoplasm 76
Both Macrophage Cell Lines Show Significant Uptake of Bare Nanoshells ............. 78
Murine Macrophages Endocytosed More PEGylated Than Bare Nanoshells ............ 82
Macrophages Infiltrated The Spheroids ...................................................................... 82
Laser-Activated Nanoshell Therapy Delayed Spheroid Growth In ACBTs Only ...... 87
Macrophages Cannot Be Double-Loaded Simultaneously Or Sequentially ............... 92
CHAPTER 4

DISCUSSION ......................................................................................... 95

CHAPTER 5

CONCLUSION..................................................................................... 107

REFERENCES ............................................................................................................... 108
VITA ............................................................................................................................... 117

v

LIST OF FIGURES
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22
Figure 23
Figure 24
Figure 25
Figure 26
Figure 27
Figure 28
Figure 29
Figure 30
Figure 31
Figure 32
Figure 33
Figure 34

Synthesis of gold nanoshells ............................................................................ 3
The effect of increasing the core: shell ratio on the plasmon resonance
absorption wavelength of gold nanoshells. ...................................................... 7
Components of the laser system ..................................................................... 10
The EPR effect ............................................................................................... 15
Opsonization of nanoparticles and their clearance by the liver ...................... 16
Stealthing and targeting of gold nanoshells.................................................... 17
The concept of magnetic domains at the nanometer scale ............................. 20
The difference between gadolinium and SPIO as contrast agents ................. 23
The incidence of glioblastoma in CNS gliomas ............................................. 26
Genetic abnormalities of primary and secondary GBM ................................. 28
TMZ mode of action....................................................................................... 36
Implantation of Gliadel wafers ...................................................................... 37
Drugs targeting growth factor signaling pathways ........................................ 39
Peptide-based cancer vaccines ...................................................................... 42
TAMs and tumor hypoxia .............................................................................. 49
The tumor spheroid......................................................................................... 52
Use of nanoparticle-loaded macrophages in an in vitro glioma spheroid
model.............................................................................................................. 53
Use of macrophages loaded with gold nanoshells and SPIO in an in vivo
glioma model ................................................................................................. 54
Visualization of the Ferumoxide injection tract ............................................ 72
The calibration curve for ICP-AES measurements of Ferumoxide................ 73
Dose-dependent internalization of Ferumoxide in murine and rat
macrophages .................................................................................................. 74
The calibration curve for the MTS assay of murine macrophages ................. 75
Response of murine macrophages to NIR laser irradiation ........................... 76
Bright field TEM images of nanoshell-loaded murine macrophages ............ 77
Absorbance curves of bare and PEGylated nanoshell solutions as supplied
by the manufacturer ....................................................................................... 79
Uptake of bare nanoshells by murine macrophages ....................................... 80
Uptake of bare nanoshells by rat macrophages .............................................. 81
Uptake of PEGylated nanoshells by murine macrophages............................. 83
Co-incubation of P388D1 macrophages and C-6 spheroids........................... 84
Co-incubation of NR8383 macrophages and ACBT spheroids ..................... 85
ACBT spheroids infiltrated by rat macrophages ............................................ 86
Effect of laser-activated nanoshell therapy on ACBT and C-6 tumor
spheroid growth .............................................................................................. 91
Simultaneous loading of gold nanoshells and Ferumoxides in murine
macrophages ................................................................................................... 92
Sequential loading of gold nanoshells and Ferumoxides in murine
macrophages ................................................................................................... 93

vi

ACKNOWLEDGEMENTS
I am forever indebted to my advisor, Dr. Madsen, for his outstanding and diligent
supervision throughout my thesis work.
I would also like to thank my committee members: Dr. Patton and Dr. Sudowe for
putting up with many questions and concerns, Dr. Hirschberg for his advice in the field of
brain tumors, and Dr. Landers for his mastery of clinical statistics and for his eagerness to
guide me through its mysteries.
I am also grateful for Mary Turner and VanVo for their technical assistance, for Julie
Bertoia for her ICP-AES help, for Dr. Longzhou Ma for his patience and TEM help, and
for Narek Gharibyan for his UV/Vis spectrophotometry help.
Finally, my deepest thanks are for my parents and my brothers (Ameen and Abdullah)
and sisters (Tahani and Layaly) for their emotional support and prayers though thousands
of miles away, for my mother-in-law and my brothers-in-law (Anas, Hussameddine and
Muhammad) for believing in me despite my complaints, and first and foremost, for my
dear husband Muhieddine, for standing by me through it all and being always there.

vii

CHAPTER I
INTRODUCTION
1.1 Nanoparticles
Nanotechnology is the recently-emerged multidisciplinary field that is concerned with
the design and utilization of nanostructures <500 nanometers (nm) in size, referred to as
‘nanoparticles’ (Cuenca et al. 2006; Euliss et al. 2006). These particles have sparked
interest when it was noticed that they have novel properties (optical, magnetic, thermal,
and biological) when compared to bulk materials, which were attributed to size scale and
time scale changes (Roco 1999).
The small size implies size confinement effects, such as the fact that nanoscale shape
variations can affect the wavelike properties of electrons. Additionally, nanoparticle
interactions occur at length scales that are comparable to particle size (such as magnetic
and laser wavelengths), which results in new phenomena, exemplified by the unusual
optical and magnetic properties of nanoparticles. Time scale changes, observed as an
increase in the speed of processes associated with nanoparticles, are attributed to smaller
distances (Roco 1999; Narducci 2007).
Some of the major classes of nanoparticles with promising properties that can be
exploited with atomic-level control include quantum dots, magnetic nanoparticles, lipid
and (non)biodegradable polymeric nanoparticles, carbon-based nanotubes (CNTs), and
metallic nanorods, nanospheres, and nanoshells (Zharov et al. 2005b; Euliss et al. 2006;
Huang et al. 2007a; Hamoudeh et al. 2008).
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For the sake of this thesis, the focus will be on two types of nanoparticles, namely
gold nanoshells and iron oxide nanoparticles, belonging to metal nanoshell and
superparamagnetic nanoparticle classes respectively.
1.1.1 Metal Nanoshells
1.1.1.1 Definition
Metallic nanoparticles have gained popularity in medical diagnostic and therapeutic
fields due to the controlled flexibility of their shape, size, and synthesis, in addition to the
tunability of their optical properties (to be discussed in detail under 1.1.1.2) (Lin et al.
2005). Though various metals have been employed, gold has drawn special attention for
utilization in nanoparticle synthesis. The inert chemical properties of the noble metal i.e.
resistance to corrosion, low toxicity, ease of biomolecule conjugation to its surface
(needed for specific targeting), in addition to its widespread biomedical applications
(such as immunogold staining procedures) represent a few of its attractive properties
(Hirsch et al. 2006; Everts 2007).
Gold nanorods, nanospheres and nanoshells have been produced and their optical
properties (absorption of light at a specific wavelength) studied (Huang et al. 2007b). Of
the three nanostructures, gold nanoshells (GNSs) represent a class of photo-absorbing
agents with “tunable” optical activities (Hirsch et al. 2006; Terentyuk et al. 2009).
Developed by Oldenburg et al., they consist of a spherical dielectric silica core (50-500
nm) surrounded by a thin (5–20 nm) gold layer. Following the nucleation and growth of
the dielectric silica core and its functionalization with amine groups, gold colloid is then
adsorbed onto the surface and acts as a nucleation site for further reduction of gold from
HAuCl4 in the solution, thus forming the shell. The shell’s thickness is controlled by the
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amount of HAuCl4 added to the solution (Fig. 1) (Zharov et al. 2005b; Hirsch et al.
2006).

Figure 1. Synthesis of gold nanoshells. (Modified from:
http://mrsec.wisc.edu/Edetc/SlideShow/slides/contents/gold.html and
http://www.bioeng.nus.edu.sg/optbioimaging/colin/research.asp).

By varying the ratio of the core size to the shell thickness, the nanoshell’s optical
absorption can be tuned to peak at the wavelength required for a particular application,
which can be within a range of the optical spectrum that spans both the visible and
infrared regions (Hirsch et al. 2006; Everts 2007; Huang et al. 2007b). This is further
3

appreciated when compared to the spectrally fixed optical activity of other nanostructures
(Zharov et al. 2005b).
Gold nanoshells have shown promise in recent years as tools for the induction of
hyperthermia in cancer therapy (Zharov et al. 2005b). The utilized optical properties,
underlying physical principles, as well as the response of tissue to the induced
hyperthermia, will be discussed in detail in the following sections.
1.1.1.2 Enhanced Optical Properties
When matter is exposed to light, photons can either be absorbed or scattered at the
same incident frequency (a process known as Mie scattering). Additionally, the
electromagnetic field of the incident light can be enhanced by a process called surfaceenhanced Raman scattering (Huang et al. 2007a). Since the last two processes are
exploited in nanoparticle imaging (which is not covered in this thesis), the focus will be
on photoabsorption.
In the case of metallic nanoparticles (such as gold nanoparticles), the metal’s surface
properties at the nanometer length scale (the length scale of the electronic motion) are
dominant and thus govern the metal’s properties. When compared to the optical
properties of bulk metals, those of metallic nanoparticles are enhanced due to the unique
interaction between light and the free conduction-band electrons that are present on their
surface (Huang et al. 2006a, 2007a). The electric field of the incident electromagnetic
radiation induces a collective oscillation of these surface electrons (surface plasmons) in
strong resonance with its frequency, a process known as the surface plasmon resonance
(SPR) (Hirsch et al. 2006; Huang et al. 2007a, 2008a).
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Light absorption peaks at the SPR wavelength of the nanoparticle, and the absorption
cross-section is by itself several orders of magnitude higher than most photoabsorbing
molecules (Huang et al. 2006a; Lal et al. 2008). For example, it is six times that of
Indocyanine green, a conventional organic dye, and 4-5 times that of Rhodamine 6G, the
strongest absorbing organic dye (O'Neal et al. 2004; Huang et al. 2007a).
The plasmon resonance wavelength is dependent on the type of metal and its
dielectric constant, as well as the shape and size of the nanoparticle (Huang et al. 2008a;
Lal et al. 2008). Thus, another advantage over light-absorbing dyes is that nanoparticles
are far less susceptible to photobleaching due to the fact that their absorption properties
are dependent on a rigid metallic structure instead of labile molecular orbital electronic
transitions (O'Neal et al. 2004).
The effect of nanoparticle shape on the plasmon resonance wavelength is obvious
when studying regions of the electromagnetic spectrum that are covered by nanospheres,
nanorods and nanoshells (Huang et al. 2008a; Lal et al. 2008). For gold nanospheres,
resonance occurs in the visible spectral region at ~ 520 nm, which is the reason for the
brilliant red color of their solution. When the shape is changed from spherical to rod, two
absorption bands are observed: a stronger band in the near infrared (NIR) region due to
the oscillation of electrons along the longitudinal axis of the nanorod, and a weaker band
in the visible region (similar to the nanospheres) due to the transverse electronic
oscillation (Huang et al. 2007a, 2008a). Additionally, the absorption of nanorods is the
strongest of all the different shapes of gold nanoparticles, which means that changing the
shape from spherical to rod not only shifts the absorption wavelength from visible to the
NIR region but also increases the absorption cross section (Huang et al. 2006a).
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Furthermore, the absorption spectrum of gold nanorods can be fine-tuned by varying their
aspect ratio (length/width). Increasing the aspect ratio redshifts the longitudinal
absorption wavelength, so that it is about 800 nm for a ratio of 3.9 and can reach 950 nm
for a ratio of 9.6 (Everts 2007; Huang et al. 2008a).
For gold nanoshells, optical tunability spans the visible and NIR regions just by
varying the ratio of shell thickness to the diameter of the silica core (core:shell ratio)
(Huang et al. 2006a; Hirsch et al. 2006; Liu et al. 2008). Increasing core: shell ratio by
decreasing the gold shell thickness shifts the plasmon resonance to longer wavelengths
(Fig. 2) (Lowery et al. 2006). In other words, gold nanoshells can be easily engineered
with resonance in the NIR region, which provides an advantage over gold nanorods,
despite the nanorods’ higher absorption cross-section (Hirsch et al. 2006; Huang et al.
2008b). For example, gold nanoshells have strong absorption near 800 nm when the shell
thickness ranges over 4–8 nm and the overall size is about 50–100 nm (Huang et al.
2008a).
Regarding the nanoparticle’s size, it has been observed that smaller nanoparticles are
better absorbers, and that increasing size increases the scattering cross section as well as
causes the SPR wavelength to slightly redshift to the NIR region (Huang et al. 2008a; Lal
et al. 2008).
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Figure 2. The effect of increasing the core: shell ratio on the plasmon resonance
absorption wavelength of gold nanoshells. (Modified from ref. Hirsch et al. 2006).

1.1.1.3 Photothermal Properties upon Laser Exposure
Following the nanoparticle’s strong absorption of light, electrons are photoexcited
and a ‘heated electron gas’ is formed. Within a picosecond, it cools by exchanging its
electronic excitation energy with the nanoparticle lattice via electron-phonon interactions.
The lattice by itself cools within 100 ps by dissipating this energy to the surrounding
medium via phonon–phonon interactions (Huang et al. 2006a; 2008a). The local
environment around the nanoparticle is thus overheated due to the conversion of light
energy to heat, a phenomenon which can be optimally designed by using light radiation
(such as a laser) with a wavelength overlapping with the nanoparticle’s SPR wavelength.
This phenomenon has been exploited in cancer therapeutics under the name of plasmonic
photothermal therapy (PPTT), as coined by Huang and colleagues, to differentiate it from
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the broader photothermal therapy (PTT) in which other photothermal agents are
employed, such as Indocyanine green (Huang et al. 2008a; Stern et al. 2008).
Preferred photothermal agents are those with strong absorption cross sections and
high light-to-heat conversion efficiency, which is required to reduce the amount of laser
energy in a less invasive therapy. Based on these specifications, gold nanoshells are
viewed as highly appealing agents. They have enhanced absorption cross sections, where
a nanoshell is nearly a million fold more likely than Indocyanine green to encounter light
and convert it to thermal energy (Hirsch et al. 2003; Huang et al. 2008a). Furthermore,
their photothermal conversion efficiency is remarkable, where electron temperatures can
easily reach several thousand kelvins with low laser powers. A third advantage over
conventional dyes is that gold’s rigid structure provides stability, so that they do not
suffer from photobleaching, a common problem with dyes in PTT (Hirsch et al. 2003;
O'Neal et al. 2004; Huang et al. 2008a).
In order to induce nanoparticle-based hyperthermia in cancer tissue embedded with
nanoparticles and exposed to a laser beam, healthy tissues along the laser path should
suffer minimal heat damage. In other words, they should be optically transparent. This
problem has been encountered by other thermal treatments such as radiofrequency (RF)
ablation and magnetic thermal ablation (Huang et al. 2007b; Liu et al. 2008). However, it
can be avoided by using laser radiation of wavelengths in the “tissue optical window” or
“the window of transparency”, which typically lies in the visible and NIR regions
(Zharov et al. 2005b; Liu et al. 2008). Most biological tissue lack NIR-absorbing
chromophores, thus permitting transmission of NIR light (700–1,000 nm) with minimal
heating (Hirsch et al. 2003). Using long-wavelength laser irradiation i.e. wavelengths that
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lie in the NIR region (650-900 nm) provides a further advantage. NIR light can penetrate
tissue deeper i.e. at depths beyond 1 cm, and can thus be used for in vivo photothermal
treatment of tumors located deep within bodily tissue (Hirsch et al. 2003; Zharov et al.
2005b; Huang et al. 2006a, 2008a). Consequently, the absorption band of the
nanoparticles has to be in the NIR region or the “therapeutic optical window” set at 750
to 1100 nm, in order to preferentially absorb NIR light energy while allowing deep
penetration into tissues with minimal disruption (Huang et al. 2006a; Lowery et al. 2006;
Bernardi et al. 2008; Lal et al. 2008; Terentyuk et al. 2009).
As has been previously mentioned, silica-gold nanoshells have strong and tunable
absorption in the NIR region (Zharov et al. 2005b; Huang et al. 2007b). Thus, the
combination of two benign moieties (nanoshells and NIR light) allows a noninvasive
delivery of heat to tumor embedded with gold nanoshells. Light can be provided by
means of a low-power diode laser (Hirsch et al. 2003; Liu et al. 2008). Most reported
literature reviews on PPTT employed diode lasers with wavelengths of 805 to 810 nm
(Terentyuk et al. 2009).
Hirsch and colleagues were the first to demonstrate nanoshells as “thermal scalpels”.
Using nanoshells with a 55-nm core radius and a 10-nm thick shell exposed to a lowpower diode laser at 820 nm, they demonstrated temperatures in tumor tissue that
exceeded 70ºC (Everts 2007). For a hypoxic, low pH environment characteristic of
tumors, tumor cell death induction can be achieved by temperatures ranging between 4044 ºC (Lal et al. 2008; Liu et al. 2008).
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1.1.1.4 Tissue response to heat
Laser light can induce controlled and confined thermal damage in tumor tissue for
several reasons. Due to its monochromaticity, collimation, and coherence, it provides a
narrow beam of high light intensity that allows deep and precise tissue penetration with
minimal power loss. The need for high power output to induce efficient tumor ablation, in
addition to the problem of its nonselectivity, have been overcome by the use of
nanoshells as photothermal agents (Huang et al. 2007b, 2008a). The currently applied
design of PPTT involves the delivery of nanoshells into tumors, where they act as a
distributed heat source following their activation by NIR laser irradiation (Elliott et al.
2007).
Laser light is usually transported from the laser to the location of treatment by means
of fiber optics. The components of the laser system are therefore represented by the laser
beam source, the fiber coupler (which launches the beam into the fiber), the fiber, and the
fiber tip or probe which emits the laser light (Fig. 3) (Van Gemert et al. 1995).

Figure 3. Components of the laser system. (Modified from ref. Van Gemert et al. 1995).
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Thermal ablation is a noninvasive and benign treatment modality that relies on the
induction of elevated temperature (hyperthermia) in cancerous cells (Huang et al. 2006b,
2008b). It is also an attractive alternative to surgical excision of tumors when surgery is
not possible. Typically, tumors are heated to a temperature over 50 °C, where they are
selectively destroyed due to their poor blood supply that reduces their heat tolerance in
comparison to normal tissue (Hirsch et al. 2006; Huang et al. 2006b, 2008a, 2008b).
Primarily, tumor ablation results from heating and evaporation of tissue water, where
cancerous cells gradually lose activity and die (Van Gemert et al. 1995; Liu et al. 2008).
However, the process is neither simple nor direct, as it occurs via several mechanisms in
separate phases (Everts 2007).
Most living tissue can tolerate modest temperature elevations for limited time
durations, which induce thermal inactivation of particular enzymes or rupture of cellular
membranes. Such damage can be easily recovered from by synthesis of replacement
enzyme proteins and new membranes. However, in irreversible thermal damage, vital
enzymes are inactivated, structural proteins are denatured, and conformational changes
are induced in RNA and DNA that are so severe that the usual repair mechanisms are
useless, more so when their mediators (such as DNA and RNA transcription enzymes)
are themselves thermally destroyed. The resulting disruption of the organized cellular
assemblies such as organelles and limiting cell membranes is incompatible with survival
(Van Gemert et al. 1995; Huang et al. 2006b; Everts 2007).
The heat-induced protein denaturation is known as thermal coagulation, and is
histologically marked by structural alterations of cells and collagens (Van Gemert et al.
1995; Huang et al. 2007a, 2008a). Transmission electron microscopy (TEM) images
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demonstrate, in addition to chromatin accumulation at nuclei margins, intracellular
organelle shrinkage, aggregation or collapse. On the other hand, collagen (extracellular
fibrous proteins) in tissue undergoes hyalinization, whereby it forms amorphous masses
(Van Gemert et al. 1995).
These effects occur in the first phase of thermal injury as a direct consequence of the
applied heat. A second phase, however, represents delayed secondary effects, where cell
death occurs secondary to endothelial cell damage of the tumor microvasculature,
cytokine release, and apoptosis (Van Gemert et al. 1995; Everts 2007).
It should be noted that cells are equipped with protective mechanisms, such as the
family of heat-shock proteins (HSPs) that can inhibit apoptosis, thus furnishing cells that
survive the thermal stress with resistance and increasing tumor recurrence. Consequently,
administered thermal doses must be sufficient to destroy all tumor cells (Everts 2007).
Threshold temperatures required for photothermal therapy of cancers have been
optimized at 46 to 60 °C, at which apoptotic tumor death is induced. Lower temperatures
(39 to 45 °C) are highly undesirable, as they can induce the production of heat shock
proteins as well as accelerate biological reactions, ultimately resulting in increased tumor
growth (Curley et al. 2008; Terentyuk et al. 2009).
Temperature increases of 30-35 °C have been achieved in PPTT with gold nanoshells,
and within short dosage times (minutes) compared to those in conventional hyperthermia
(~60 min) (Huang et al. 2006b; Lal et al. 2008; Terentyuk et al. 2009). O'Neal et al.
(2004) achieved a temperature of 50°C within 30s in in vivo colon carcinoma tumors,
while Stern et al. (2008) achieved a temperature of 65.4°C within 3 minutes with full
tumor ablation for an in vivo model of human prostate cancer cells. Other research
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groups, such as Hirsch et al. and Huang et al., deduced that threshold temperatures lie
within 70-80°C range for efficient destruction of tumor cells (Huang et al. 2006b). It is
worth mentioning that laser dosages were in general 10-25 fold less than those used
earlier with Indocyanine green dye (Hirsch et al. 2003).
Since thermal damage is a temperature-time governed process, a steep rise followed
by stability in tumor temperature is essential to prevent any tissue compensatory
thermoregulation processes. Continuous laser heating meets this goal, as it is
characterized by short time kinetics, achieving a temperature maximum at 60 sec, while
the steady-state temperature is reached within 100 to 150 sec (Van Gemert et al. 1995;
Terentyuk et al. 2009).
The nanoparticle’s killing efficiency is not only dependent on target temperature
levels but on the local temperature distribution as well. This is related to tumor depth and
blood perfusion, in addition to the distribution of nanoparticles within the tumor (Van
Gemert et al. 1995; Elliott et al. 2007; Everts 2007; Huang et al. 2007a; Terentyuk et al.
2009).
Controlled and localized hyperthermia is affected by the extent to which laser light is
absorbed in the path and by thermal diffusion over surrounding tissues. Consequently,
temperatures should not be allowed to vary by more than 10 to 20 °C (Terentyuk et al.
2009).
Finally, optimal temperature distribution over the tumor volume necessitates that the
optical penetration depth be of the same magnitude as the tumor thickness (Van Gemert
et al. 1995). Practically, heating has been observed at depths beyond 1 cm, and greater
depths may be reached by using lower nanoshell concentrations (which allow deeper NIR
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tumor penetration), longer exposure times and higher laser powers. Nonetheless,
increased background tissue heating from tissue absorbing pigments can limit the
maximum laser dosage applied, and the whole approach is limited to tumors at depths <
2–3 cm, the penetration depth of NIR wavelengths (Hirsch et al. 2003; Gannon et al.
2008).
1.1.1.5 Clinical Applications in Cancer Therapy:
It has already been shown that gold nanoshells are highly attractive agents for tumor
therapy due to their biocompatibility, tunable optical properties, and easy methods of
synthesis and of bioconjugation (multi-functionalization) (Huang et al. 2007b, 2008a;
Gobin et al. 2008; Lal et al. 2008). Initial in vivo studies for nanoshell-mediated
photothermal ablation studies involved direct injection of the nanoshell suspension into
the tumor, an option that may not always be feasible. Alternatively, intravenous injection
was employed, where nanoshells circulate and accumulate at the tumor site prior to laser
treatment (Hirsch et al. 2006; Huang et al. 2008a).
1.1.1.5.1. Passive Targeting: The EPR Effect
In order to supply the expanding tumor mass, malignant tumors induce “rapid
angiogenesis” that produces structurally abnormal blood vessels with inconsistent
diameters and large gaps (up to 2 μm). These defects in the vascular architecture result in
leaky vessels that allow particles in the blood stream that are large enough to passively
extravasate and accumulate in the tumor, a process known as enhanced permeability and
retention (EPR) effect (Hirsch et al. 2006; Zaman et al. 2007; Bernardi et al. 2008; Lal et
al. 2008). Nanoshells fall within the size range of 60–400 nm applicable for the EPR
effect, thus allowing for their passive targeting in most tumor types following intravenous
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injection (Fig. 4). As has been demonstrated by Schwartz et al. (2009) and other studies,
improved survival and even complete tumor regression have been achieved (Cuenca et al.
2006; Hirsch et al. 2006; Bernardi et al. 2008; Gobin et al. 2008).

Figure 4. The EPR effect. (Modified from ref. Peer et al. 2007).

1.1.1.5.2

Stealthing and Active Targeting

Because nanoshells undergo agglomeration at physiological conditions during
systemic circulation, they suffer from opsonization, whereby opsonins (serum proteins
such as complement C3b) are attracted and bind to the nanoshell’s negatively-charged
surface. Subsequently, they are rapidly taken up and removed by the reticuloendothelial
system (RES) e.g. Kupffer cells of the liver, which limits their circulation time (Fig. 5)
(Tortora et al. 1995; Cuenca et al. 2006; Hirsch et al. 2006; Hamoudeh et al. 2008;
Terentyuk et al. 2009). Consequently, increasing circulation time improves their chances
of reaching the tumor via the EPR effect. This can be achieved by “stealthing” i.e.
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coating their surface with polymers that provide steric stabilization, thus reducing the risk
of opsonization (Hirsch et al. 2006; Everts 2007).

Figure 5. Opsonization of nanoparticles and their clearance by the liver. (Modified from:
http://www.akaike-lab.bio.titech.ac.jp/akaike/english/resarch/index.html).

The gold surface provides simple chemistry for attaching polyethylene glycol (PEG),
where PEGylated gold nanoshells have demonstrated reduced clearance and sufficient
EPR to eradicate tumors in mice with subcutaneous colon carcinoma cells (Fig. 6)
(Hirsch et al. 2003; Everts 2007; Lal et al. 2008; Terentyuk et al. 2009). This has been
demonstrated by O’Neal et al. (2004) and Hirsch et al. (Lin et al. 2005).
In addition to passive targeting, active targeting represents another modality for
improving nanoshell tumor localization, especially when the EPR effect is not present, as
in some solid tumors. In active targeting, the nanoparticle’s surface is functionalized with
proteins (as antibodies) against cell surface markers overexpressed by tumors, such as
human epidermal growth factor receptor-2 (HER2) and epidermal growth factor receptor
(EGFR) (Fig. 6) (Cuenca et al. 2006; Huang et al. 2006b; Lowery et al. 2006; Everts
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2007; Bernardi et al. 2008; Lal et al. 2008). This insures the selectivity of therapy that is
crucial when dealing with circulating metastatic or residual cells in order to spare normal
cells (Zharov et al. 2005a). Halas and colleagues showed that only breast cancer cells
incubated with gold nanoshells conjugated to anti-HER2 antibodies were damaged under
laser irradiation (Huang et al. 2008a).

Figure 6. Stealthing and targeting of gold nanoshells. (Modified from ref. Reddy et al.
2006).

1.1.2 Superparamagnetic Nanoparticles
1.1.2.1 Definition and Types
Magnetic resonance imaging (MRI) is a non-invasive technique that can provide
anatomic, physiological and metabolic/functional information with high spatial and
temporal resolution. Nanotechnology has stepped in to provide attractive, nanosized MRI
contrast agents with greater magnetic susceptibility than traditional MR contrast agents
such as gadolinium (Cuenca et al. 2006; Neumaier et al. 2008; Orringer et al. 2009).
Conventional paramagnetic contrast agents are generally metal chelates with unpaired
electrons (paramagnetic) (Neumaier et al. 2008). Iron has been preferred for synthesizing
paramagnetic nanoparticles due to its biocompatibility and high magnetization. However,
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being easily oxidized has led researchers to design iron-oxide (IO) based nanoparticles
(Sun et al. 2007; Orringer et al. 2009). Though iron oxide particles have been used as
magnetic contrast agents for more than 45 years, the last decade has witnessed refinement
in their synthesis and the addition of coating, mainly dextran. The added biocompatible
surface coating has reduced their toxicity and thus increased by one order their lethal
dose level (LD50) (Thorek et al. 2006; Choi et al. 2007a).
Superparamagnetic iron oxide contrast agents (SPIO) are a new class that was
initially developed in the late 1980s (Cuenca et al. 2006). They consist of a waterinsoluble core comprised of multiple iron oxide crystals. These can be magnetite (Fe3O4)
and/or maghemite (γ Fe2O3), encased in hydrophilic coating. Both iron oxide
compositions have similar lattice parameters and magnetic properties. The nanoparticle’s
name is derived from superparamagnetism, a phenomenon that occurs because the size of
the ferromagnetic crystals is smaller than the ferromagnetic domain (~30 nm) (Thorek et
al. 2006; Neumaier et al. 2008). This will be explained in detail under 1.1.2.2.
SPIO are categorized based on their overall diameter (which includes the iron oxide
core and the hydrated coating) into oral SPIO (300-3500 nm), standard SPIO (60–150
nm), and ultrasmall SPIO (USPIO) of 10–40 nm (Thorek et al. 2006; Neumaier et al.
2008). The focus will henceforth be on standard SPIO, which will be referred to as SPIO.
SPIO-enhanced MRI applications have seen tremendous advances, from imaging of
macrophage activity to tumor diagnosis (Park et al. 2007). Ferumoxides (such as
Feridex® IV) are already FDA-approved for liver imaging. Their core consists of
aggregates of iron crystals incompletely coated with Dextran T-10, and have a
hydrodynamic size of 120–180 nm (mean particle size is 58.5 nm). USPIO, such as

18

Ferumoxtran-10 (Combidex®), have also reached human evaluation, though still in
clinical trials. They have monocrystalline cores completely coated with a thicker dextran
layer, and have a smaller hydrodynamic size (15–30 nm) (Varallyay et al. 2002; Corot et
al. 2004; Raynal et al. 2004).
1.1.2.2 Magnetic Properties
The magnetic properties of ferromagnetic materials result from aligned single
electron spins. Their magnetic domains (Weiss domains), in the absence of an externally
applied magnetic field, are aligned at short range only, whereas adjacent domains are
anti-aligned at the long range. The transition region in between such magnetic domains is
called a Bloch wall. Bloch walls are thermodynamically not favored at the nanometer
scale (~14 nm). Consequently, single domain crystals are formed only, and are
characterized by a strong paramagnetic nature, hence called superparamagnetic (Fig. 7)
(Thorek et al. 2006). When compared to paramagnetic materials, superparamagnetic
materials (such as SPIO) have larger magnetic susceptibility i.e. larger ability to augment
an external magnetic field because the entire crystal aligns in the direction of the applied
field (Bushberg et al. 2002; Thorek et al. 2006).
MR contrast materials enhancing T2 decay are usually susceptibility agents that can
disrupt the local magnetic field, generating a detectable change in the MR signal i.e.
image contrast (Bushberg et al. 2002; Thorek et al. 2006). They decrease the spin-spin
relaxation time (T2) by inducing energy exchange between the atomic nuclei and thus
dephasing of proton spin (Choi et al. 2007a). SPIO significantly reduce T2 time, resulting
in a strong decrease in signal intensity (negative enhancement). Additionally, their nonhomogeneous distribution causes substantial disturbances in the local magnetic field,
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which further accelerates the loss of phase coherence of surrounding protons. This
increases the susceptibility effect of the measured spin-spin relaxation time (T2*), since
T2* is dependent on the homogeneity of the main magnetic field (Bushberg et al. 2002;
Corot et al. 2004; Thorek et al. 2006; Neumaier et al. 2008).

Figure 7. The concept of magnetic domains at the nanometer scale. (Modified from:
www.magnasense.fi/technology.html and from ref. Brooke et al. 2001).

Clinically, SPIO are mainly used for the acquisition of T2- and T2*-weighted
sequences. It has also been shown that they can induce positive enhancement by
decreasing the spin-lattice relaxation time (T1) sufficiently to generate contrast in a T1weighted sequence. Therefore, SPIO have both high T1 and T2 relaxivities, more so
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when compared to traditional MRI contrast agents such as gadolinium chelates that are
often employed for T1-weighted imaging (Bushberg et al. 2002; Corot et al. 2004;
Thorek et al. 2006; Choi et al. 2007a; Neumaier et al. 2008). SPIO can be detected in
vivo at concentrations as low as 1 µg (Varallyay et al. 2002).
1.1.2.3 Clinical Applications in Cancer Diagnosis
SPIO have been employed in a wide range of biomedical applications, from MRI
contrast enhancement to hyperthermia (Sun et al. 2007). The scope of this thesis will be
limited to their use as MRI contrast agents, specifically for the detection and delineation
of tumors. SPIO have many characteristics that have increased their popularity over
Gadolinium chelates. They are composed of biocompatible iron that can be cellularly
recycled, and have a dextran coating that allows active targeting via linkage of ligands.
Additionally, they induce strong hypointensive signal changes per unit of metal on T2*weighted images, and their magnetic properties can be tailored based on their size. This is
further appreciated when compared to Gadolinium chelates that are not biocompatible
and have lower relaxivity values (Zimmer et al. 1995; Neumaier et al. 2008).
1.1.2.3.1 Passive Targeting: Uptake by Macrophages and Use in Glioma
Enhanced retention in tumors and macrophage phagocytosis represent two of the
most common mechanisms by which SPIO localize at tumors for MR imaging. Higher
SPIO accumulation improves the acquired T2-weighted images by enhancing the
transverse spin dephasing of protons. The size and the surface properties of SPIO
particles affect their pharmacokinetics, organ distribution, opsonization and cellular
uptake following their intravenous administration (Thorek et al. 2006; Neumaier et al.
2008).
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Due to their thin, incomplete dextran coating which allows protein-binding, SPIO are
rapidly opsonized then taken up from the blood circulation by cells of the
reticuloendothelial system (RES) in the spleen and liver as well as circulating blood
phagocytic cells. Consequently, they have a short plasma half-life of 8–30 minutes. On
the other hand, USPIO, due to their smaller size, have lower liver uptake, which results in
a plasma half-life of 25–30 hours. This allows for uptake by peripheral tissue
macrophages and thus widespread tissue distribution, reaching lymph nodes and bone
marrow (Varallyay et al. 2002; Cuenca et al. 2006; Jackson et al. 2007; Petry et al. 2007;
Neumaier et al. 2008).
This difference in pharmacokinetics is reflected in the current clinical applications of
SPIO and USPIO. Ferumoxide (SPIO) was the first specific contrast agent for hepatic
imaging, and is currently used for the detection of focal liver lesions of hepatocellular
carcinoma. Ferumoxtran (USPIO) is in Phase III clinical trials for lymph node metastasis
detection, an application that cannot be met with Ferumoxide due to its short half-life
(Raynal et al. 2004; Jackson et al. 2007; Petry et al. 2007).
The uptake of SPIO by the circulating blood phagocytes which then migrate to
inflammatory sites has been cleverly exploited in MRI diagnosis. Originally developed
for in vivo lymphoma monitoring, the loading of the circulating macrophages with SPIO
contrast agents has recently been employed for the noninvasive observation of tumors,
particularly in the central nervous system (CNS), where both the high macrophage
phagocytic activity and the tumor’s leaky vasculature are involved (Thorek et al. 2006;
Petry et al. 2007).
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In high-grade brain tumors such as glioblastoma, intravenous gadolinium produces
T1 enhancement at the periphery of the tumor, which reflects a leaking blood-brain
barrier (BBB) (Zimmer et al. 1995; Corot et al. 2004). Iron oxide particles induce tumor
enhancement by passing through disrupted BBB as well. However, following their
accumulation in the tumor interstitium, they are endocytosed by phagocytes and
surrounding tumor cells found at tumor margins (Fig. 8). This, in addition to their
decreased diffusion coefficient (owing to their larger size), results in their persistence and
consequently a more accurate delineation of the margins and of micrometastases than
with gadolinium, which freely diffuses over time into the surrounding brain (Varallyay et
al. 2002; Thorek et al. 2006; Neuwelt et al. 2009; Orringer et al. 2009). Such peripheral
definition has highlighted the opportunity of their use for preoperative and intraoperative
surgical planning using Intraoperative MR imaging (IMRI), as well as postoperative
assessment of surgical resection (Varallyay et al. 2002; Neuwelt et al. 2004; Hunt et al.
2005; Thorek et al. 2006).

Figure 8. The difference between gadolinium and SPIO as contrast agents. (Modified
from ref. Neuwelt et al. 2009).
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Specifically, in the case of gliomas, the poor visual contrast between gliomas and
normal brain tissue observed with gadolinium has led to a wider adoption of iron oxide
particles. However, it was observed that the intracellular iron uptake was nonspecific i.e.
iron oxide particles were being internalized by reactive cells (astrocytes and
macrophages), not tumor cells, at the tumor margin (Varallyay et al. 2002; Neuwelt et al.
2004; Meng et al. 2007).
SPIO suffered from several drawbacks that limited their use as intravenous contrast
agents. Their short plasma half-life, large particle size, and shape irregularity has limited
their ability to cross the incompetent BBB, resulting in minimal tumor signal intensity
changes as compared with USPIO (Varallyay et al. 2002). However, macrophage uptake
has sparked a new application: MRI detection of macrophages in brain tumors. Iron oxide
nanoparticles are incorporated by macrophages in vivo, which then colocalize with brain
tumors. As shown by Petry et al. (2007), this technique proved more efficacious in highgrade than low-grade gliomas, and may help to differentiate between brain tumors and
areas of radiation necrosis.
1.1.2.3.2 Active Targeting
Active targeting, or molecular tumor targeting, of SPIO has been highly facilitated by
their hydrophilic coating that allows conjugation of targeting agents, such as antibodies.
Such tumor-specific contrast agents can induce a different signal intensity in tumor tissue
compared to normal tissue. Targeted ligands are usually tumor- associated antigens that
are overexpressed by cancer cells (Thorek et al. 2006; Neumaier et al. 2008; Orringer et
al. 2009). Examples include human epidermal receptor 2 (HER-2) and matrix
metalloproteinase-2, a membrane-bound endopeptidase that is upregulated in gliomas.
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Following SPIO binding, receptor-mediated endocytosis improves their site-specific
accumulation and hence MR sensitivity (Cuenca et al. 2006; Thorek et al. 2006).

1.2 Glioblastoma Multiforme (GBM)
1.2.1 Definition
Central nervous system (CNS) tumors are responsible for about 2% of all cancer
deaths, where almost 50% of these are gliomas (Chandana et al. 2008; Maru et al. 2008).
The most common subtype of primary brain tumor, gliomas derive their name from glial
cells, which are support cells for neurons. Due to their aggressive and invasive nature,
they are the second leading cause of death from neurologic disease (after stroke) and are
among the deadliest of human cancer types (Hart et al. 2008; Martin et al. 2009).
The World Health Organization (WHO) uses cellular origin and histologic
appearance as the basis for classifying primary brain tumors (Chandana et al. 2008).
Tumors derived from astrocytes (a subtype of glial cells) are called astrocytic tumors
(astrocytomas) and represent the majority of CNS primary tumors. Based on their
histologic appearance, astrocytomas are graded as pilocytic astrocytoma (grade I),
astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme
(GBM) (grade IV) (Gomez and Kruse 2006; Hoelzinger et al. 2007; Hart et al. 2008;
Maru et al. 2008; Yamanaka 2008). While grades I and II tumors are considered low
grade, the higher grade tumors (grades III and IV) are more proliferative and can
infiltrate the peritumoral margin and disperse to distant sites, resulting in a shorter time to
recurrence than lower grade tumors (Hoelzinger et al. 2007; Chandana et al. 2008).
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1.2.2 Statistics and Risk Factors
Glioblastoma multiforme (GBM) is the most common type of glioma (50.7%) and the
most malignant form of astrocytoma (Fig. 9) (Gomez and Kruse 2006; Chandana et al.
2008; La Rocca and Mehdorn 2009). Associated with significant morbidity and mortality,
GBM occurs at an annual frequency of 3 cases per 100,000 people in the United States,
and is more common among Caucasians (approximately double that observed in African
Americans). About 90% of GBMs arise de novo from glial cells and are termed primary
GBMs. These are more common in older patients and have a typical clinical history of
less than 6 months. Secondary GBMs transform over months or years from preexisting
lower-grade gliomas and occur predominantly in younger patients (Reardon and Wen
2006; Chandana et al. 2008; Maru et al. 2008; Sathornsumetee and Rich 2008).

Figure 9. The incidence of glioblastoma in CNS gliomas. (Modified from ref. La Rocca
and Mehdorn 2009).
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The clinical history of GBM is usually less than three months in more than 50% of
cases, whereas the current median survival of GBM patients after first-line therapy is
14.6 months (Maier-Hauff et al. 2007; Yamanaka 2008; Martin et al. 2009). Despite the
fact that the past 30 years have witnessed tremendous advances in diagnostics and
multimodal treatments (surgery, radiotherapy and chemotherapy), only seven months
have been added to the mean survival rate of GBM patients. Additionally, they have a
high frequency of recurrence due to their highly invasive nature, whereby invasive
glioma cells lie beyond the reach of current localized therapies. Patients with recurrent
GBM have a median survival duration of only 25 weeks, and they suffer from the
detrimental effects of aggressive therapies (Hoelzinger et al. 2007; Maier-Hauff et al.
2007; Debinski 2008; Sathornsumetee and Rich 2008; Selznick et al. 2008; Martin et al.
2009).
Risk factors for GBM include several genetic alterations (discussed in the next
section) and several environmental factors. Substantial proof has only been associated
with high-dose ionizing radiation while remaining inconclusive for other suggested
factors such as alcohol use, smoking, head trauma, and exposure to chemical agents
(solvents, pesticides) (Chandana et al. 2008).
1.2.3 Clinical Picture and Molecular Biology
GBM is a highly cellular tumor that is characterized by poorly differentiated,
pleomorphic cells, endothelial proliferation, and necrosis. It also exhibits resistance to
apoptotic stimuli, evasion of immunosurveillance, tissue invasion, and angiogenesis.
Symptoms depend on the location, size, and growth rate of the tumor. Seizures are a
common presenting manifestation, in addition to headaches, speech difficulties, and
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changes in mental status. When occurring in the frontal lobe, other symptoms may
present such as changes in behavior or personality (Reardon and Wen 2006;
Sathornsumetee and Rich 2008; Yamanaka 2008).
Several genetic alterations have been associated with GBM. These include cell cycle
regulatory pathways (p53 and p16), growth factor receptors (EGF and PDGF), signaling
pathways (PTEN) and others (Maru et al. 2008; Selznick et al. 2008; Yamanaka 2008).
Additionally, subtle differences exist between genetic abnormalities of primary and
secondary GBMs (Fig. 10).

Figure 10. Genetic abnormalities of primary and secondary GBM. (Modified from ref.
Sathornsumetee and Rich 2008).
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Primary GBM is characterized by overexpression (>60% of cases) of the epidermal
growth factor receptor (EGFR) gene, which is involved in the control of cell
proliferation. The upregulation of EGFR has been positively correlated with GBM
malignancy, and its defect can also increase activity of an important signaling pathway
i.e. the phosphatidylinositide-3-kinase (PI3K)/AKT pathway which controls cellular
processes contributing to normal homeostasis and malignancy. Additionally, primary
GBM exhibits amplification and overexpression of murine double minute 2 (MDM2), a
protein which forms a complex with tumor protein 53 (TP53), thereby abolishing its
activity (control of cell growth). Other mutations include p16 deletion and mutation of
the tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on
chromosome ten) which occurs mainly in primary GBMs (32%) and rarely (4%) in
secondary GBMs. It should be mentioned that PI3K/AKT overactivity may also result
from loss of PTEN, since it acts as a negative regulator of PI3K function (Reardon and
Wen 2006; Sathornsumetee and Rich 2008; Yamanaka 2008).
While some genetic abnormalities are common in both primary and secondary GBMs
(such as PTEN mutations), secondary GBM is characterized by the inactivation of the
TP53 gene, which normally induces cell cycle arrest and DNA repair in response to
genotoxic stress. Its inactivation is therefore associated with abnormal cell division.
Another genetic hallmark of secondary GBMs is the overexpression of the plateletderived growth factor (PDGF) and its receptors. Platelet-derived growth factor (PDGF) is
a major mitogen for glial cells that is recognized by two types of cell surface receptors,
PDGFR-α and PDGFR-β, which also regulate the PI3K/AKT pathway. PDGFR-α has
been implicated in tumor cell proliferation in both early and late stages of glioma
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development (Reardon and Wen 2006; Sathornsumetee and Rich 2008; Yamanaka 2008).
Finally, the tumor-suppressor gene p53 mutations have been reported in 30–60% of
malignant gliomas, and are more common in secondary than primary GBMs (Selznick et
al. 2008).
1.2.4 Diagnosis and Prognosis
Currently, an invasive biopsy is performed to confirm the diagnosis, as it provides
information about the location and histological type, and hence the grade and the
potential aggressiveness. With the use of advanced imaging modalities and stereotactic
framing devices, neurosurgeons are now capable of performing deep brain biopsies with
accurate tumor localization. Computed tomography (CT) and magnetic resonance
imaging (MRI) have been used for diagnosis and treatment planning, though they suffer
from a major drawback: the quantitation of the actual tumor volume is hindered by the
edema build-up around the tumor site that masks the tumor margins and regions of
infiltrating tumor cells. The use of contrast agents to overcome this problem has not
proven very effective. These agents are supposed to allow tumor domain estimates from
the largest cross-sectional area of contrast enhancement (which indicates a disrupted
BBB). However, they tend to diffuse away from blood vessels, displacing the exact
location (Gomez and Kruse 2006; Parvez 2008).
Both positron emission tomography (PET) and magnetic resonance spectroscopy
(MRS) have recently been used to increase the accuracy of the biopsy, as they can better
define metabolically-active areas of tumor. Moreover, functional or echo planar MRI has
been employed for preoperative mapping of brain tissue (Parvez 2008).
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The prognosis of patients with GBM is influenced by patient age, neurological
condition, functional status, tumor location, histological and molecular features, and
extent of surgical resection. Patients aged below 60 years have a better prognosis. The
Brain Tumor Cooperative Group trials demonstrated that half of the patients younger than
40 years survived for 18 months versus only 10% of patients older than 60 years. Absent
or minimal neurological signs present another favorable prognostic factor, though
patients with seizures are an exception, most probably because they are diagnosed earlier.
Additionally, a Karnofsky performance status (KPS) score of 70 or greater is considered
good, as 34% of patients in this category were alive at 18 months versus 13% of patients
with lower scores. A better prognosis was also noted in patients with tumors located in
the deep gray matter than those with lobar tumors, and in patients with frontal lobe
tumors compared to those with temporal or parietal lobe tumors. Finally, patients with
absent extensive necrosis, hypermethylation of the MGMT (methyl guanine and methyl
transferase) gene promoter, and a small residual tumor after surgery i.e. near-total
resection have also shown improved survival (Reardon and Wen 2006; Hoelzinger et al.
2007; Chandana et al. 2008; Sathornsumetee and Rich 2008; Yamanaka 2008; La Rocca
and Mehdorn 2009).
GBM has a very poor prognosis, is rapidly progressive and resistant to therapy
despite advances in its management. Several factors prevent the complete eradication of
GBM. To start with, tumor resection is severely hindered by the poor visual contrast
between cancerous and normal brain tissue and, as such, aggressive gross resection often
impairs the patient’s quality of life. Unfortunately, limited resection may leave residual
glioma cells in the margins. An additional complicating factor is the highly invasive
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nature of GBMs which makes a complete resection almost impossible. At the time of
surgery, cells are already migrating away and invading normal brain tissue, and in >90%
of the cases give rise to a recurrent tumor adjacent to or within 2 cm of the primary tumor
site (Veiseh et al. 2005; Gomez and Kruse 2006; Maier-Hauff et al. 2007; Debinski 2008;
Hart et al. 2008; Parvez 2008; Lefranc et al. 2009).
Another limiting factor is the resistance of GBMs to therapy, which is due to their
location as well as genetic, morphological and molecular heterogeneity. Their physical
isolation by the BBB prevents efficient penetration of systemically administered
chemotherapeutic agents. Furthermore, their genetic instability and cellular heterogeneity
(between patients and within tumors) ensures resistance to chemotherapy and radiation
therapy. Other contributing factors include their well developed neovasculature, and the
current inability to identify residual resistant hypoxic tumor cells (Gomez and Kruse
2006; Maier-Hauff et al. 2007; Debinski 2008; Parvez 2008; Sathornsumetee and Rich
2008).
1.2.5 Therapy of GBM
Following histological diagnosis, GBM management is based on symptomatic relief
and increasing survival with multimodality treatments. In addition to
glucocorticosteroids, which improve neurological symptoms by reducing peritumoral
edema, established therapies include surgical resection, radiation therapy, and
chemotherapy (either locally with wafers or systemically) (Hart et al. 2008;
Sathornsumetee and Rich 2008; La Rocca and Mehdorn 2009).
Because surgery coupled with radiation is not able to improve median survival rates
beyond 6 to 9 months, chemotherapy is used as adjuvant therapy after surgery. Inevitable
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recurrences have been treated with surgical re-resection, local therapies with carmustineimpregnated wafers, immunotherapies, targeted drug therapies and combination
therapies. Many of these modalities are still in clinical trials, and the 6-month
progression- free survival (PFS-6) has become a widely acceptable endpoint for phase II
trials due to its better correlation with overall survival (Koo et al. 2006; Reardon and
Wen 2006; Sathornsumetee and Rich 2008; La Rocca and Mehdorn 2009).
1.2.5.1 Surgery
Although GBM is surgically incurable, resection remains the first option. The goal is
to achieve maximal resection while preserving neurological function. Although near-total
resection remains the most that is achieved, it has nonetheless improved functional status
and survival by decreasing tumor burden and relieving the intracranial pressure.
Following a comprehensive neurosurgical evaluation, the final decision for complete
resection is based on several factors, including the tumor’s location, histopathology, and
presence of comorbid conditions. To minimize damage to crucial structures near the
tumor bed, CT and MRI scanners are employed to guide the resection in real time by
allowing the assessment of tumor volume in its current anatomic location (Koo et al.
2006; Reardon and Wen 2006; Chandana et al. 2008; Hart et al. 2008; Parvez 2008;
Sathornsumetee and Rich 2008).
Due to the drawbacks of residual tumors associated with high recurrence rates and of
unresectable tumors, adjuvant therapies such as radiation have been developed (Koo et al.
2006; Parvez 2008).
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1.2.5.2 Radiation Therapy (RT)
Radiation therapy (RT) has become part of the standard management as adjuvant to
surgery to improve local control and survival. Initial randomized studies have shown
increases in median survival up to nine months with 50–60 Gy of whole brain RT
(WBRT) administered following surgery. This improvement was noted regardless of the
degree of resection (Reardon and Wen 2006; Hart et al. 2008; Parvez 2008).
Radiation can be delivered either externally or internally. Conventional external beam
RT started with WBRT but is now replaced by involved field RT (IFRT), which utilizes
imaging to minimize normal brain irradiation. One example of IFRT is 3D-conformal RT
(3D-CRT), which employs CT in treatment planning that is guided by dosimetric
software, and can further be assisted with MRI. Treatment planning is a cooperative
effort of radiation oncologists, radiation physicists, and dosimetricists, and involves the
fine adjustment of beam energy, field size and shape. Typically, 25 to 35 daily treatments
are administered over 5 to 7 weeks (Chandana et al. 2008; Parvez 2008).
In addition to conventional external beam radiation, stereotactic radiotherapy (SRT)
is another type of external delivery that also uses 3D planning to deliver narrowly
collimated ionizing radiation beams in multiple fractions. When given in a single dose in
a one-day session, it is referred to as stereotactic radiosurgery (SRS) that is used for small
volumes of recurrent GBM or as a boost after conventional external beam RT (Chandana
et al. 2008; Parvez 2008).
In addition to photons, heavy particles such as helium ions, protons, and neutrons
have been used. They have the advantage of overcoming the tumor’s hypoxic
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microenvironment and of inducing more DNA damage that is additionally less
susceptible to repair as compared to photons (Parvez 2008).
Interstitial RT (brachytherapy) represents an internal method of radiation delivery,
whereby seeds of 125I are surgically implanted into the tumor. This modality delivers
large radiation doses to the tumor in a continuous fashion, therefore decreasing repair of
the induced sublethal damage (Chandana et al. 2008; Parvez 2008).
RT efficiency is limited by the emergence of resistant cells, decline of cognitive
function in adults and of brain development in children, and the risk of secondary
malignancies (Koo et al. 2006).
1.2.5.3 Chemotherapy
Adjuvant therapy has expanded to include chemotherapy, in addition to RT, to
improve tumor responsiveness (Reardon and Wen 2006; Hart et al. 2008). The inability
to cross the BBB has imposed restrictions on chemotherapeutic agents of choice (Koo et
al. 2006). The traditional chemotherapy cocktail employed is PCV i.e. Procarbazine,
Lomustine (CCNU), and Vincristine, which was shown in a meta-analysis to be
associated with a two-month improvement in median survival (Parvez 2008). However,
significant clinical benefit has been demonstrated recently with temozolomide (TMZ), an
imidazotetrazine alkylating agent. Newly diagnosed GBM patients treated with TMZ and
RT showed median survival of 14.6 months in an international, multi-center phase III
trial (Reardon and Wen 2006; Sathornsumetee and Rich 2008; La Rocca and Mehdorn
2009; Lefranc et al. 2009). In a 2008 meta-analysis by Hart et.al, TMZ was also shown to
be effective as primary therapy for GBM without a significant risk of early adverse
events.
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Being small and lipophilic, orally administered TMZ can cross the BBB. It leads to
the formation of O6-methylguanine in DNA which mispairs with thymine during DNA
replication, whereby cells undergo G2/M arrest and ultimately die (Fig. 11). In addition,
TMZ is capable of inducing late apoptosis in glioma cells, and has been shown to be less
toxic to hematopoietic cells in the bone marrow (Lefranc et al. 2009).

Figure 11. TMZ mode of action. (Modified from ref. Neidle and Thurston 2005).

Significant morbidity has generally been associated with chemotherapy due to its low
therapeutic index and severe systemic side effects. Moreover, the development of multidrug resistance (MDR) has prompted combinational chemotherapy. This resistance has
been due in part to the drug efflux system P-glycoprotein, a cellular transporter expressed
on the luminal membrane of the cerebral endothelium that expels a number of
chemotherapeutic drugs (Koo et al. 2006; Hart et al. 2008). Another mechanism of
resistance that has gained importance in GBM is the MGMT gene, which encodes for an
alkyl transferase responsible for the tumor resistance to alkylating and methylating agents
(Chandana et al. 2008). Ultimately, the ongoing trend for improving treatment efficacy is
to combine chemotherapy with other modalities such as targeted therapy or
immunotherapy (Sathornsumetee and Rich 2008).
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1.2.5.4 Local Therapy
Due to the fact that surgical resection can result in the release of angiogenic and
growth factors that stimulate residual tumor cells, local therapy is applied to the resection
cavity during surgery to limit recurrence and increase the time for local progression. This
can either be by controlled-release systems or direct infusion of the drug. Controlled drug
delivery involves degradable polymers that allow constant diffusion of drugs into the
cavity. The only drug delivery system that has received both US and European approval
is the carmustine (BCNU) wafer (Gliadel® Implant). Initially approved for use in patients
with recurrent GBM, it is now also used for newly diagnosed patients as an adjunct to
surgery and radiation (Parvez 2008; La Rocca and Mehdorn 2009; Lefranc et al. 2009).
Gliadel wafers consist of carmustine embedded in a sterile, biodegradable, inert
matrix that are implanted (up to 8) in the tumor cavity during surgery (Fig. 12) and allow
controlled release of carmustine over a period of days to weeks. Compared with placebo,
survival advantage was seen in GBM patients receiving carmustine wafers at the time of
initial surgery, with both groups receiving radiotherapy after surgery (Parvez 2008; La
Rocca and Mehdorn 2009; Lefranc et al. 2009).

Figure 12. Implantation of Gliadel wafers. (ref. Lesniak and Brem 2004).
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The safety of carmustine wafers has been established, though cases of delayed
cerebral edema have been recorded and may represent a reaction to tumor necrosis. The
absence of systemic toxicity further warrants their combination with other treatment
modalities (Parvez 2008; La Rocca and Mehdorn 2009).
1.2.5.5. Targeted Therapy
As has been previously mentioned, growth factors such as EGF, PDGF, and vascular
endothelial growth factor (VEGF) regulate proliferation and survival pathways.
Overexpression or mutation of their receptors has been implicated in GBMs, and is
associated with cellular proliferation, invasion, and angiogenesis. Since these receptors
share a common mechanism of signaling pathway activation i.e. tyrosine kinase activity,
low-molecular-weight kinase inhibitors have been designed to target molecules in these
signaling pathways, and their small size is favorable for CNS delivery. Additionally,
monoclonal antibodies of these ligands or their receptors have been developed (Reardon
and Wen 2006; Sathornsumetee and Rich 2008).
1.2.5.5.1

Inhibition of Growth Factor Signaling Pathways (EGFR and PDGFR)

Two small-molecule kinase inhibitors of EGFR have been evaluated in malignant
gliomas: Erlotinib (Tarceva®) and gefitinib (Iressa®). Erlotinib appears to be more
effective than gefitinib for radiographic response rate, but no improvement in overall
survival was observed with either. A chimeric monoclonal antibody against EGFR,
cetuximab (Erbitux®), was also investigated in a preclinical setting and showed benefit
alone and in combination with radiation (Fig. 13) (Reardon and Wen 2006;
Sathornsumetee and Rich 2008).
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Figure 13. Drugs targeting growth factor signaling pathways. (Modified from refs.
Reardon and Wen 2006; Sathornsumetee and Rich 2008).

Imatinib mesylate (Gleevec®) is a tyrosine kinase inhibitor of PDGFR that
demonstrated preclinical antitumor activity but has so far failed to show benefit in several
phase II trials as monotherapy. It has, however, significantly enhanced the cytotoxic
effect of radiation in a human glioblastoma cell line, and has shown some promise in
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combination with temozolomide in a recent phase I trial (Fig. 13) (Reardon and Wen
2006; Sathornsumetee and Rich 2008).
1.2.5.5.2

Inhibition of Angiogenesis: VEGF Pathway

Malignant gliomas are highly vascularized tumors, and VEGF is one of many
angiogenic factors implicated in the tumor’s angiogenesis. Its pathway can be targeted
either at the level of VEGF ligands or of their receptors (VEGFR) (Reardon and Wen
2006; Sathornsumetee and Rich 2008).
Bevacizumab (Avastin®) is a recombinant humanized monoclonal antibody targeting
VEGF that is the first FDA–approved antiangiogenic agent for cancer therapy. Its
efficacy has been mainly demonstrated as a combination agent and is therefore discussed
under 1.2.5.7. On the other hand, VEGFR inhibition has been demonstrated by kinase
inhibitors such as vatalanib and sorafenib in preclinical or early clinical trials (Fig. 13)
(Reardon and Wen 2006; Sathornsumetee and Rich 2008).
1.2.5.5.3

Inhibition of Intracellular Effectors: PI3K/AKT Pathway

GBM resistance to radiotherapy and chemotherapy has been linked in several
publications to an activated PI3K/AKT pathway, and Shing et al. have even demonstrated
the restoration of chemotherapy efficacy following its inhibition (Lefranc et al. 2009). It
has also been previously mentioned that this pathway is activated by EGFR, PDGFR, and
PTEN, whose involvement in GBM proliferation and resistance has already been
described. Inhibitors of this pathway target PI3K in addition to downstream intracellular
effectors, mainly AKT and mammalian target of rapamycin (mTOR). Perifosine (an AKT
inhibitor), PI-103 (an inhibitor of both PI3K and mTOR), and temsirolimus (an mTOR
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inhibitor) are undergoing clinical evaluation (Fig. 13) (Reardon and Wen 2006;
Sathornsumetee and Rich 2008).
1.2.5.6 Immunotherapy
Despite the fact that the brain is an immunologically privileged organ, it is not
completely isolated from systemic immunity. This has led to the application of
immunotherapeutic strategies that enhance local or systemic immune machinery for an
antitumor response. According to Selznick et al. (2008), these strategies can be
categorized into (i) antitumor vaccination that establishes a systemic cellular antitumor
immune response, (ii) cytokine immunotherapy that enhances local immune responses,
and (3) passive immune-based targeting of other treatment modalities (such as RT and
chemotherapy) by conjugation to monoclonal antibodies targeting tumor cells.
1.2.5.6.1 Antitumor Vaccination
The simplest vaccination strategy entails using peptide-based cancer vaccines (Fig.
14). Following their injection, they are captured by antigen presenting cells (APCs),
which move to regional lymph nodes and present the ingested peptides to naïve cytotoxic
T cells (CTLs). CTLs recognizing a peptide on APCs become activated, migrate into the
tumor site, and can recognize the peptide-expressing tumor cells and eliminate them.
Prolonged survival was noted in patients vaccinated with glioma peptides in comparison
to those receiving chemotherapy and RT (Selznick et al. 2008; Yamanaka 2008).
One of the many promising vaccination strategies employs dendritic cells (DC),
professional antigen presenting cells that are involved in immune surveillance. In this
strategy, autologous DCs from tumor-bearing hosts are expanded ex vivo and pulsed with
tumor antigens, which they can ingest and present. Once reintroduced to the host, they
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can recruit and activate (prime) T cells with antigen specificity within lymphoid organs.
T cells activated in the periphery cross the BBB and can directly kill tumor cells, thus
generating a tumor-specific immune response. DCs pulsed with glioma cell lysates
(multiple glioma antigens) have already been applied in Phase I and II clinical trials
(Selznick et al. 2008; Yamanaka 2008).

Figure 14. Peptide-based cancer vaccines. (Modified from:
www.landesbioscience.com/curie/chapter/4276).

Another vaccination strategy is adoptive immunotherapy, whereby tumor-infiltrating
lymphocytes (TILs) are harvested from a peritumoral location, expanded and stimulated
ex vivo by interleukin-2 (IL-2), followed by reimplantation. The difference in this
strategy is that antigen priming is not required, since TILs are already tumor-specific due
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to their presence at the tumor site (Selznick et al. 2008). The role of IL-2 is further
explained below.
1.2.5.6.2 Local Cytokine Immunotherapy
Cytokines are secreted proteins that can modulate antitumor immunity i.e. inhibit or
potentiate an existing immune response, depending on their type. Due to their systemic
toxicity, immunostimulating cytokines have been delivered locally as therapeutic targets
for malignant glioma. One example is IL-2, a T-cell secreted cytokine that can stimulate
the proliferation of activated T and B cells (Selznick et al. 2008).
1.2.5.6.3 Passive Immune-based Targeting
Monoclonal antibodies that target tumor-specific epitopes have been engineered with
high selectivity and affinity, and are mainly delivered locally due to BBB restrictions to
an adequate, systemic delivery. Their use for targeting conjugates (such as nanoparticles)
has already been mentioned. One example of a targeted epitope is the interleukin-13
receptor alpha 2 (IL13Rα2), whose expression has been demonstrated in adult and
pediatric GBMs, while being virtually absent from normal brain tissue (Jain 2007;
Bernardi et al. 2008; Sathornsumetee and Rich 2008).
1.2.5.7 Combination Therapies
GBM resistance has led investigators to combine treatment modalities to achieve the
most therapeutic benefit. Following the combination of RT and surgery, the addition of
chemotherapy (TMZ) to RT has been established in newly diagnosed GBM patients
(Reardon and Wen 2006). A Phase III trial has shown that daily, low-dose TMZ with RT
followed by adjuvant, standard-dose TMZ improved median progression-free survival,
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overall survival, and two-year survival as compared with RT alone (median survival was
14.6 versus 12.1 months) (Chandana et al. 2008; Parvez 2008).
When TMZ activity was found to be significantly compromised in patients with
overexpressed MGMT, interest arose in adding BCNU to TMZ. A recent meta-analysis
showed another advantage for this combination that stems from the difference in the
time-to-peak effect for each agent. BCNU implants provide immediate antitumor activity
with a peak clinical benefit within the first year, while TMZ (usually used after surgery
with RT followed by a monthly maintenance dose) has a peak clinical benefit around 18
months-later than the peak benefit for BCNU implants. This implies that a staged
sequential benefit can be gained by this combination. Thus, the combination of surgery,
chemotherapy (TMZ and BCNU), and RT will most likely become the new standard of
care (Reardon and Wen 2006; La Rocca and Mehdorn 2009).
Other attempted combinations include the combination of TMZ with irinotecan, a
chemotherapeutic agent that is a topoisomerase inhibitor. Furthermore, targeted therapy
has been combined with RT or chemotherapy, and some of these combinations have
already been mentioned. Others include the combination of irinotecan with bevacizumab,
which has shown a significant radiographic response rate of 63% and a PFS-6 of 32% in
a phase II trial. Combinations of different strategies within targeted therapy, such as
receptor inhibitors with inhibitors of downstream signaling pathways, have also shown
promise for the treatment of GBM (Reardon and Wen 2006; Parvez 2008;
Sathornsumetee and Rich 2008).
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1.3 Macrophages
1.3.1 Definition and Properties
Macrophages are a class of white blood cells that are derived from myeloid
progenitor cells in the bone marrow. Their precursors are monocytes that differentiate
into macrophages following their migration from the circulation into tissue where they
reside (Owen et al. 2004; Murdoch and Lewis 2005). For example, microglia are the
resident tissue macrophages of the CNS (Carson et al. 2008). Macrophages are the first to
mediate host immune responses against foreign objects. Besides their role as
“professional phagocytes” i.e. the ingestion (endocytosis) of the invading pathogen, they
can also release several growth factors, cytokines and interleukins such as transforming
growth factor-β (TGF-β), platelet-derived growth factor (PDGF), interleukin-1 (IL-1),
tumor necrosis factor-α (TNF- α), in addition to nitric oxide (NO) that trigger other
inflammatory responses and mediate repair of damaged tissues (Metz et al. 2004; Raynal
et al. 2004; Hsiao et al. 2008).
The endocytic process can be broadly subdivided into phagocytosis and pinocytosis.
Whereas phagocytosis involves internalization of large particles, pinocytosis involves
soluble material and nanoparticles, and can either be nonspecific or receptor-mediated.
Raynal et al. have shown that the scavenger receptor A (SR-A), normally involved in
cleaning up cellular debris during host defense, may be implicated in the endocytosis of
nanoparticles, specifically Ferumoxides (Raynal et al. 2004). The subsequent
compartmentalization in secondary lysosomes within the cytoplasm has already been
detailed (Metz et al. 2004).
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1.3.2 Implications in Glioma
1.3.2.1 Tumor-Associated Macrophages (TAMs) and Microglia
Tumors are not only composed of neoplastic cells and vasculature, but infiltrating
leukocytes, in particular macrophages, represent an important component. Such
macrophages are referred to as tumor-associated macrophages (TAMs), which are
derived from peripheral blood monocytes that are recruited into the tumor, and comprise
up to 50% of the tumor’s cellular mass (Murdoch and Lewis 2005; Knowles and Harris
2007).
In GBM, it has been shown that TAMs can constitute up to a third of the tumor mass.
The large macrophage population infiltrating gliomas and outlining its borders includes,
in addition to TAMs, local microglia which have proliferated and/or migrated into the
tumor (Jackson et al. 2007; Kennedy et al. 2009; VanHandel et al. 2009). At the tumor
margins, their numbers are threefold higher than those of TAMs, implying that they are
the main responders to the tumor burden (Hoelzinger et al. 2007).
Though originally thought to exert antitumor response, GBM-infiltrating TAMs have
been recently reported to be functionally impaired. There is increasing evidence that
tumors “educate” TAMs not only by inducing the loss of TAMs’ tumoricidal function but
also by rendering them immunosuppressive and capable of promoting tumor angiogenesis
and progression. This was derived from the fact that high levels of macrophage
infiltration have been associated with poor prognosis. Instead of the classical M1
macrophages, TAMs are now mainly the M2 phenotype that responds to tumor-secreted
factors with pro-tumorigenic functions i.e. secreting immunosuppressive cytokines,
proangiogenic growth factors and proteolytic enzymes. Peritumoral microglia have also
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been shown to contribute to GBM invasion and angiogenesis through the secretion of
cytokines such as TNF-α, IL-1, and EGF (Murdoch and Lewis 2005; Choi et al. 2007b;
Hoelzinger et al. 2007; Knowles and Harris 2007; Kennedy et al. 2009).
1.3.2.2 Recruitment of Macrophages: Chemokine Attraction
In order for tumors to exploit macrophages for their benefit, they need first to recruit
them to their site. For that purpose, tumors induce a chemoattractive gradient by secreting
a number of factors, most important of which are chemokines (Choi et al. 2007b;
Hoelzinger et al. 2007). Chemokines are small peptides that regulate leukocyte
trafficking into inflammation sites, and include two major groups: the CXC and the CC
chemokines. In tumors, chemokines have been associated with additional protumorigenic roles such as local tumor cell growth and invasion (Maru et al. 2008).
In GBM, the chemokine (CXC motif) receptor 4 (CXCR4) and its ligand (CXCL12)
have been found to be overexpressed. Other studies have confirmed that signaling
through CXCR4 and CXCL12 recruits microglia to the peritumoral area and can also
mediate glioma cell invasion and angiogenesis. Moreover, other CXC chemokines have
been implicated such as CXCR1 and the angiogenic CXCL8. Of the CC chemokine
group, the production of CCL3 (macrophage inflammatory protein-1a) by astroglial cells
has been reported. In addition to chemokines, other cytokines and growth factors can also
recruit macrophages from the circulation, such as colony stimulating factor-1 (CSF-1)
and VEGF (Murdoch and Lewis 2005; Hoelzinger et al. 2007; Maru et al. 2008).
1.3.2.3 TAMs and Tumor Hypoxia
The centers of many solid tumors, in addition to tumor spheroids cultured in vitro,
have been observed to be hypoxic i.e. of a low oxygen level. This results from rapid
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tumor growth that surpasses the angiogenic rate. Consequently, tumors reach a size that
places cells within the core at large distances from their nearest blood supply, and the
diffusion of oxygen and nutrients becomes insufficient to meet their metabolic demands.
Hypoxic tumor cores are therefore largely necrotic, and can influence tumor
aggressiveness, response to therapy, and the patient’s overall survival. This is because
hypoxic cells adapt by a reduced proliferation rate which renders them less responsive to
chemotherapies that kill dividing tumor cells. Moreover, they are less responsive to
radiotherapy due to the absence of oxygen-derived free radicals essential for radiationinduced DNA damage. As a result, hypoxia produces aggressive tumor cells that have the
potential to repopulate and metastasize. In GBM, regions of hypoxia are common (Owen
et al. 2004; Murdoch and Lewis 2005; Choi et al. 2007b; Flynn et al. 2008).
TAMs have also been seen in high density in hypoxic tumor areas, where it is
hypothesized that, being phagocytic scavenger cells, they are attracted by signals released
by cells undergoing necrosis. In addition, it has been shown that hypoxic tumor cells
recruit TAMs by an increased rate of production of macrophage chemoattractants such as
VEGF. Following their migrations, hypoxic tumor cells entrap TAMs by downregulating
chemokine receptors and chemoattractants and upregulating MIF (macrophage migration
inhibitory factor), as was seen in GBM. The net result is the accumulation of TAMs
within areas of hypoxia / necrosis, where they are exploited to produce factors that
promote tumor angiogenesis (Fig. 15) (Owen et al. 2004; Murdoch and Lewis 2005;
Knowles and Harris 2007).

48

Figure 15. TAMs and tumor hypoxia. (Modified from ref. Karin and Greten 2005).

1.3.3 Use of Macrophages as Delivery Vehicles
The ability of macrophages to migrate and accumulate within tumor tissue,
specifically in hypoxic regions, has rendered them attractive vehicles for the delivery of
diagnostic or therapeutic agents to sites of tumorigenesis. The most basic concepts of
such a strategy involve the isolation of monocytes from a given patient, which are
differentiated ex vivo into macrophages, loaded with the agent of interest, and then
reinjected into the patient (Owen et al. 2004; Murdoch and Lewis 2005; Knowles and
Harris 2007; Beduneau et al. 2009).
In the case of gliomas, the use of autologous macrophages offers several advantages.
Several studies have already confirmed the accumulation of systemic macrophages in
glioma models, which improves the selectivity as well as reduces the toxicity of the
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intravenous administration. This is because injected macrophages will either migrate into
the chemoattractive tumor or into reticuloendothelial organs (liver and spleen) for
elimination. Furthermore, their sampling and reinjection into patients is far easier when
compared to other techniques involving non-circulating cells such as stem cells (Valable
et al. 2008).
In the field of nanoparticle applications, the use of macrophages as a cell-based
delivery vehicle has stemmed from the observation that systemically administered
nanoparticles, such as SPIO used for MRI, were ingested by macrophages. The
advantages gained by such a delivery system include an increase in the nanoparticles’
systemic half-life by protecting them from reticuloendothelial elimination. Additionally,
the macrophages’ endocytic capacity highly facilitates their loading (Metz et al. 2004;
Engberink et al. 2008; Hsiao et al. 2008; Beduneau et al. 2009).
Metz et al. (2004) conducted in vitro experiments for the optimization of monocyte
labeling techniques with SPIO for use as in vivo MRI contrast agents. Recently,
Engberink et al. (2008) labeled monocytes in vitro with SPIO and was able to track them
in vivo with MRI into sites of neuroinflammation, whereas Valable et al. (2008)
completed these findings by demonstrating that exogenous iron-oxide labeled
macrophages were capable of infiltrating small (less than 10 mm3) as well as large (2570 mm3) glioma brain tumors in rats. Subsequent T2*-weighted MR imaging revealed the
invasion of the entire tumor mass by the labeled macrophages, with a higher density at
the borders.
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1.4 Use of Macrophages Loaded with Gold Nanoshells and SPIO for GBM
The attractions of using gold nanoshells for thermal therapy in GBM have already
been outlined, along with the many difficulties encountered with targeting systemically
administered doses. Though passive targeting, i.e. relying on the EPR effect for tumor
localization has been employed, it remains a very limited approach when the goal is to
accumulate gold nanoshells within the central hypoxic regions of the tumor (where
resistant cells reside) because of the reduced blood flow. Consequently, a strategy that
can deliver the gold nanoshells within the tumor microenvironment is required, whereby
heat induced by NIR irradiation ablates the very cells that ultimately produce recurrence
and metastasis, therefore highly impacting the patient’s mortality (Choi et al. 2007b; Lal
et al. 2008).
Such a promising delivery strategy has been developed by Choi et al. (2007b) and
coined “Trojan Horse”. It literally involves using TAMs, naturally recruited by the
hypoxic tumor’s chemoattractive gradient, for the delivery of their endocytosed load of
therapeutic nanoshells.
Following the incubation and endocytosis of the gold nanoshells by macrophages, the
authors showed that the loaded nanoshells did not affect the macrophages’ viability that
is crucial for their recruitment and transport. On the other hand, the nanoshells’ resonant
optical absorption properties were preserved, as subsequent illumination with a pulsed
NIR laser at 754 nm resulted in tumor ablation in an in vitro hypoxic model of breast
tumor spheroids.
The use of spheroids for modeling the hypoxic tumor microenvironment has been
previously validated. Spheroids are composed of layers of cells across which an oxygen
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gradient exists, starting with normoxia at the outer layers and becoming progressively
more hypoxic until a necrotic core is formed at the center (Fig. 16) (Choi et al. 2007b).
Choi et al. were able to show that macrophages were not only intercalated among the
outer hypoxic layers but were distributed throughout the entire spheroid.

Figure 16. The tumor spheroid. (Modified from ref. Bearer and Cristini 2008).

1.5 Scope of Study
The use of macrophages loaded with gold nanoshells for thermal ablation of GBM
tumors is an attractive, relatively safe approach that has not yet been explored by any
research group. Proving its feasibility in an in vitro glioma spheroid model, and with the
use of continuous wave (CW) laser light for ablation, represents the first challenge, prior
to its in vivo application (Fig. 17). An additional challenge lies in the use of SPIO in the
gold-nanoshell loaded macrophages for the purpose of MRI tracking of the Trojan Horses
following their systemic injection in the in vivo model (Fig. 18).
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Figure 17. Use of nanoparticle-loaded macrophages in an in vitro glioma spheroid model.
(Spheroid image modified from ref. Folkman and Hochberg 1973).

The primary objective of this thesis is to examine the ability of gold nanoshell-loaded
macrophages to act as vehicles that can deliver their thermoablative load into glioma
tumor spheroids, and the ability of the phagocytosed nanoshells to ablate the tumor cells
following their laser activation. It is hypothesized that: (1) macrophages can efficiently
uptake gold nanoshells, (2) nanoshell-loaded macrophages can infiltrate glioma spheroids
following co-incubation, (3) laser irradiation of the infiltrated spheroid can activate the
phagocytosed nanoshells and result in significant delay/ arrest of tumor spheroid growth
and (4) macrophages can efficiently uptake both SPIO and nanoshells. So far, the double
loading of macrophages with two types of nanoparticles (a therapeutic and a diagnostic
type) has not been attempted. Therefore, the efficient functioning of the macrophage and
of its therapeutic cargo, in the presence of SPIO, needs to be established in the in vitro
spheroid model prior to the in vivo experiments.
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Figure 18. Use of macrophages loaded with gold nanoshells and SPIO in an in vivo
glioma model. (Images modified from: http://www.rsc.org/images/polyketals300_tcm18-51513.jpg, s3.images.com/huge.55.275275.jpg and from ref. Atwater 2007).
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CHAPTER 2
MATERIALS AND METHODS
2.1 Cell Lines
Two cell lines were used for macrophages: the murine macrophage-like cell line
P388D1 (ATCC# CCL-46) and rat alveolar macrophages NR8383 (ATCC# CRL-2192).
For cancer cells, the rat glioma cell line C-6 (ATCC# CCL-107) and the human grade IV
GBM cell line (ACBT- G. Granger, University of California, Irvine) were used. All cell
lines were maintained in Dulbecco Modified Eagle Medium (DMEM) with high glucose
(Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 25
mM HEPES buffer (pH 7.4), penicillin (100 U/ ml) and streptomycin (100 µg/ ml) at
37°C and 5% CO2.
Cell lines were maintained in T-25 flasks and passed twice weekly. P388D1 cells
grow in suspension and were passed at a ratio of 1:100. NR8383 is a semi-adherent cell
line that requires scraping during passing. Briefly, cells were detached by gentle scraping
with a scraper then subcultured at a ratio of 1:2.
Both C-6 and ACBT are adherent cell lines that were maintained as monolayers.
Briefly, confluent flasks were emptied of media, washed with Gibco phosphate buffered
saline (PBS) (Invitrogen Corp., Carlsbad, CA), then detached using Gibco 0.25%
Trypsin-EDTA (Invitrogen Corp., Carlsbad, CA) for 5 minutes. Following 1:5 dilution of
the trypsinized cells with DMEM, cells were seeded in new flasks at a ratio of 1:50 for C6 cells and 1:5 for ACBT cells
For experiments, C-6 cells and ACBT cells were grown as spheroids. Cells were
seeded in separate T-25 flasks 3 days earlier. 70% confluent flasks were then harvested,
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resuspended in 20 ml DMEM, and transferred to a square dish coated with a 1:1 solution
of 2 % agarose and 2X DMEM. Spheroids were formed within 7 days, and their growth
was followed until a size of 250-350 µm was reached. The medium was replaced twice
weekly with fresh 15 ml of DMEM.

2.2 Nanoparticles
Feridex I.V® (Advanced Magnetics, Inc., Cambridge, MA, USA) was used for SPIO.
It is a suspension of Ferumoxides (mean particle size of 58.5 nm) that delivers 11.2 mg
Fe per ml. AuroShellTM particles (Nanospectra Biosciences Inc., Houston, TX, USA)
were used for gold nanoshells. They are supplied as a suspension of bare gold nanoshells
in de-ionized (DI) water, and consist of a 120-nm diameter silica core encased in a gold
shell of ~ 15 nm in thickness (total particle diameter of ~150 nm) . Two batches were
used: one at a concentration of 3.205 x 109 particles/ml was used solely for loading
macrophages intended for TEM imaging, while the other had a concentration of 4.285 x
109 particles/ml, and was labeled to have a peak absorbance of 1.6 at λ = 819 nm. A batch
of PEGylated nanoshells was also procured from the same source for comparison
purposes. The suspension consists of the same nanoshells with a PEG layer at the surface
estimated to have a thickness of 5-10 nm, and was supplied at a concentration of 2.814 x
1011 particles/ml, with a peak absorbance of 1.22 at λ = 795 nm for a 100x diluted aliquot.

56

2.3 Ferumoxides:
2.3.1 MR Imaging
Experiments were performed in a 7 T horizontal small bore scanner (Bruker,
Billerica, MA, USA). Images were acquired ex vivo on a paraformaldehyde-fixed Fischer
rat brain. Prior to imaging, 0.2 ml of Feridex® was injected directly into the excised brain.
T2*-weighted gradient echo MR pulse sequences (TR/TE = 1600/10 ms; flip angle = 30o,
FOV = 35 mm; slice thickness = 1.0 mm) were used to detect the iron oxide particles.
2.3.2 Uptake in Macrophages
Macrophages (2.5 x 106 cells for P388D1 and 1 x 106 cells for NR8383) were
incubated with variable concentrations of Feumoxide (100, 200, 400 and 600 µg Fe/ml)
for 24 hr at 37°C in 5% CO2. Cells incubated without Ferumoxides represented the blank.
Four runs were performed per concentration, and each run had its own blank.
The amount of iron taken up by the cells was quantified using inductively coupled
plasma atomic emission spectrometry (ICP-AES). Briefly, cells were transferred into 15ml centrifuge tubes and centrifuged at 600 rpm for 7 min. The resultant cell pellet was
washed two times with phosphate-buffered saline (PBS) so as to remove all particles not
endocytosed, while centrifuging and discarding the supernatant in between washes. After
suspending in fresh PBS and counting, the cell number was adjusted to be the same in the
blank and the samples by transferring the calculated volume into new 15-ml centrifuge
tubes and centrifuging. The final cell pellet was then transferred to an epitube and
mineralized in a heat block adjusted at 80°C with 70% HNO3 for 1.5 hr. 20 µl of 30%
H2O2 were added, and then mineralization was presumed for another 3.5 hr. Samples
were then diluted with DI water to obtain a HNO3 concentration of 5% in a final volume
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of 10 ml, then filtered using a 0.45-µm membrane and stored at +4°C until ICP-AES
analysis.
Samples were measured using an iCAP 6500 series (Thermo Scientific, Inc.,
Cambridge, UK) ICP-AES at λ = 238.2 nm. Calibration was performed with five
standards freshly prepared from SPEX CertiPrep Iron Standard (CAT# CLFE 2-2 Y) at
concentrations of 0, 1, 2.5, 5, 15 and 25 ppm Fe in 5% HNO3.
The amount of iron in picograms (pg) was calculated from the iron concentration
(ppm) detected by the instrument by:
Fe amount (pg) = Measured [Fe] (ppm or mg/L) x Sample volume (L) x 109 pg/mg
where sample volume is 10 ml. The blank reading was not subtracted from the sample
reading because it was below detection limit in all runs and was thus assigned a value of
zero. Finally, the intracellular amount of iron (pg/cell) was obtained by dividing the
amount of iron (pg) by the number of cells in each run, then averaging the results of the
four runs for each Ferumoxide concentration.

2.4 NIR Laser Irradiation of Macrophages in Absence of Nanoshells
Five thousand P388D1 macrophages in a total volume of 50 µl were transferred per
well of a 384-well plate. 4 wells were used per group. Laser ablation was accomplished
using an Intense laser source Model 7404 (Intense, North Brunswick, NJ, USA) at λ =
805.5 nm. The laser output power was calibrated with a Lasermate/D external power
meter (Coherent, Santa Clara, CA, USA).Wells were irradiated with various power
densities ranging from 1 to 10 W/cm2, after which 50 µl of fresh media was added, and
the cells were transferred to wells of a 96-well plate for colorimetric assay.
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Following incubation for 24 hr, viability was assessed using the colorimetric MTS
assay (Promega, USA). Briefly, each well was incubated with 20 μl of MTS/PMZ for 4
hr in a shaker at 37 °C and 50 rpm. Absorbance was then read at 490 nm with an Infinite
M1000 plate reader (Tecan Systems Inc., San Jose, CA, USA). The percent viability of
the cells was expressed as the ratio of absorbance of irradiated cells relative to that of
non-irradiated cells (after subtracting the absorbance of the blank “medium” from each)
multiplied by 100. A calibration curve was established using P388D1 cell densities of 0,
1250, 2500, 5000, 10000 and 25000 cells incubated with MTS/PMZ under similar
conditions.

2.5 Gold Nanoshells
2.5.1 TEM Imaging
2.5 x 106 P388D1 macrophages were incubated with 3.205 x 109 nanoshells for 24 hr
at 37°C in 5% CO2. The cell suspension was then transferred to an epitube and
centrifuged at 600 rpm for 7 min. The cell pellet was washed three times with PBS,
centrifuging and discarding the supernatant in between washes.
The final cell pellet was fixed with freshly prepared 2.5% gluteraldehyde in 0.1 M
sodium cacodylate buffer for 1 hour at room temperature. Following centrifugation and
removal of the fixative, the pellet was washed three times with 0.1 M cacodylate buffer
(10 minutes each), centrifuging and discarding the supernatant in between washes. Then,
the pellet was post-fixed with 1% osmium tetroxide (OsO4) in 0.1 M cacodylate buffer
for 1 hour at room temperature.
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The post-fixative solution was removed and followed by three washings with 0.1 M
cacodylate buffer (10 minutes each). Cells were then gradually dehydrated with acetone
solutions of increasing concentrations (30%, 50%, 70%, 90% and 100%), each added for
10 minutes then pipetted off. After a second 10-minute addition of 100% acetone, the
fixed and dehydrated cells were gradually infiltrated with acetone: EMbed-812 resin
solutions of increasing resin concentration (3:1, 1:1 and 1:3), each added for 8 hr then
pipetted off.
The cell pellet was finally embedded in pure resin mixture for 8 hr, which was
replaced with fresh resin mixture and allowed to polymerize by placing the epitube in a
hot oven at 60°C for 24 hr, producing a resin block that was removed from the epitube
after cooling.
The resin block was trimmed then sectioned using a Leica EM UC6 ultramicrotome
(Leica, Germany) fitted with a trimmer (CryoTrim 20, Diatome, USA) then a diamond
knife (Ultra 45º, Diatome, USA). The ultra-thin sections (95 nm) were then mounted on
200-mesh copper support grids (Electron Microscopy Sciences Cat.# G200-Cu) then
post-stained as follows in order to create contrast.
In a petri dish, drops of pure ethanol were mounted on a piece of parafilm then mixed
with equal-sized drops of 5% uranyl acetate. Grids were stained with uranyl acetate by
mounting them on drops for 30 minutes, after which they were washed with DI water and
allowed to dry for 10 minutes. Meanwhile, another petri dish was rendered CO2-free
using NaOH pellets, and on a piece of parafilm, drops of Reynold’s lead citrate were
mounted, then the grids were stained as before for 3 minutes, after which they were
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washed with DI water, allowed to dry for 10 minutes, then transported in a grid box (Ted
Pella Cat.# SB100) for TEM examination.
The stained sections were examined with a TECHNAI G2 F30 S-Twin transmission
electron microscope (FEI, USA). TEM bright field images were taken.
Materials used in the preparation of the TEM sections were prepared as follows. The
2.5% gluteraldehyde fixative solution was prepared by mixing 1 ml of 25%
gluteraldehyde aqueous solution (Electron Microscopy Sciences Cat.# 16200), 5 ml of
0.2 M sodium cacodylate buffer pH 7.4 (Electron Microscopy Sciences Cat.# 11650),
333.4 µl of 12% formaldehyde, and 3666.6 µl of DI water to give a final volume of 10
ml. 12% formaldehyde was diluted with DI water from 36% formaldehyde solution
(EMD Cat.# FX0415-4).
The 0.1 M sodium cacodylate buffer pH 7.4 used for washing was diluted 1x from 0.2
M stock solution (mentioned above). The post-fixative 1% osmium tetroxide was
prepared by mixing equal portions of 2% aqueous osmium tetroxide solution (Electron
Microscopy Sciences Cat.# 19152) and 0.2 M sodium cacodylate buffer pH 7.4.
The dehydrating acetone solutions were prepared using appropriate dilutions of the
stock 100% acetone solution (EMD Cat.# AX0125-4).
The pure embedding resin Embed-812 (Electron Microscopy Sciences Cat.# 14120)
was prepared according to the manufacturer’s instructions. Briefly, all kit components i.e.
the resin EMbed-812, the anhydride solutions DDSA and NMA, and the accelerator
DMP-30 were warmed to 60ºC. Then, mixture A (EMbed-812 and DDSA) and mixture B
(EMbed-812 and NMA) were prepared separately by thorough mixing of their
components in the specified volumes, after which the two mixtures were blended, a
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specified volume of DMP-30 added, and the final embedding solution subjected to
thorough mixing (imperative to achieving uniform blocks).
The 5% uranyl acetate solution used for staining was prepared by adding a measured
weight of 2.5g of uranyl acetate dihydrate powder (Electron Microscopy Sciences Cat.#
22400) to 50 ml of DI water in a beaker, which was then covered with foil, stirred
overnight, and subsequently stored at 4 ºC. To prepare 50 ml of the second stain
(Reynold’s lead citrate), 1.33 g of lead nitrate powder (Electron Microscopy Sciences
Cat.#17900) and 1.76 g of sodium citrate dihydrate granules (Electron Microscopy
Sciences Cat.#21140) were measured and added in the mentioned order to a beaker
containing 30 ml of DI water (solution becomes cloudy when sodium citrate is added).
Then, 5 ml of 1 N NaOH solution (Electron Microscopy Sciences Cat.# 21170-01) were
added (solution becomes clear), the solution was stirred for 10 minutes to dissolve, then
brought to a final volume of 50 ml with DI water and stored at 4 ºC (3-6 months).
2.5.2 Uptake in Macrophages
The uptake of nanoshells in macrophages was studied using a UV-Vis-NIR
spectrophotometer. 5 x 106 P388D1 cells and 1 x 106 NR8383 cells were incubated with
4.285 x 109 nanoshells (1 ml) for 24 hr at 37°C in 5% CO2.
Following incubation, macrophages were transferred to 15-ml centrifuge tubes,
centrifuged at 600 rpm for 7 min, then washed twice with PBS to remove un-endocytosed
particles, while centrifuging and discarding the supernatant in between washes. The final
cell pellet was suspended in 3 ml of DMEM, and the absorbance of the resultant cellular
suspension measured with a Varian UV-Vis-NIR spectrophotometer (Cary 6000i, Varian,
USA).
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Absorbance was measured at a spectrum involving 600-1100 nm wavelengths, which
covers the broad absorption peak of nanoshells (819 nm). To calculate % uptake of
nanoparticles, reference solutions containing nanoparticles in absence of macrophages
were used, and were prepared in the same solution (media) as that used for macrophage
incubation, and at the same dilution ratio. Background correction is necessary to obtain
absorbance values corresponding to nanoparticles only i.e. without medium interference.
Consequently, solutions prepared by substituting the nanoparticle volume added with DI
water were measured, and their absorbance values subtracted from the nanoparticle
solution absorbance values to give the pure absorbance of the nanoparticle.
The absorbance of endocytosed particles only i.e. without macrophage interference is
needed to calculate % uptake. Consequently, macrophages incubated under similar
conditions (same number, total volume, incubation time) in absence of nanoparticles
were similarly washed then suspended in 3 ml DMEM. The resulting solution was
measured, and its absorbance values subtracted from those of the macrophage groups to
give the pure absorbance of the endocytosed nanoparticle.
% uptake of nanoshells was calculated by:

where AM+ N is the absorbance of endocytosed nanoshells at λ= 819 nm, and AN is the
absorbance of the reference nanoshell solution at the same wavelength.
For P388D1 macrophages, a second group involving the incubation of 5 million
macrophages with 1.407 x 1011 PEGylated nanoshells was run under similar conditions to
study if an increase in the number of nanoshells can increase uptake, even if they are
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PEGylated. Corresponding background corrections were performed as before; however,
the high number of nanoshells used required dilution, so that % uptake was calculated by:

where AM+ N is the absorbance of endocytosed nanoshells at λ= 795 nm, AN is the
absorbance of the reference nanoshell solution at the same wavelength, and D.F. is the
dilution factor (= 1.42) applied.
To validate the % uptake computed experimentally, the absorbance values of the
reference nanoshell solution were multiplied by the computed % uptake and plotted
versus wavelength to produce a simulated uptake curve.
According to Beer’s law, the absorbance A of a given substance in solution, measured
at a given wavelength λ, is directly proportional to its concentration in that solution. The
relationship is given by:
Aλ = ε C L
where ε is the solution’s molar absorptivity (also called molar absorption coefficient or
molar extinction coefficient) in M-1 cm-1, C is the solution’s molar concentration in M,
and L is the light pathlength (i.e. the width of the sample cuvette) in cm. For 1 cm-width
sample cuvettes, the relation becomes:
Aλ = ε C
The nanoshell solution with a reference concentration (CR) was supplied by the
manufacturer with a reference peak absorbance (AR) at a given wavelength λ.
Consequently, the concentration of nanoshells in samples (CS) was calculated by:
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where AS is the absorbance of nanoshells in the sample measured at the same wavelength
λ. The number of nanoshells endocytosed by macrophages was then computed by
multiplying CS by the sample volume.

2.6 Spheroids and Macrophages
2.6.1 Loading Macrophages with Nanoparticles
The pairing of P388D1 macrophages with C-6 spheroids and NR8383 macrophages
with ACBT spheroids was followed in all experiments. Macrophages (2 x 106 for
P388D1 and 1 x 106 for NR8383) were incubated for 48 hr at 37°C in 5% CO2. Two
groups were used: macrophages incubated in medium only (representing empty
macrophages), and macrophages incubated with 4.285 x 109 nanoshells (1 ml).
2.6.2 Incubation of Spheroids with Macrophages
On the day of incubation of spheroids with macrophages, the wells of a 48-well plate
were each coated with 250 µl of a 1:1 solution of 2 % agarose and 2X DMEM. After
solidification, 750 µl DMEM was added to each well. Spheroids in the average diameter
range of 250-350 µm were then picked using a microscope with a calibrated eyepiece
micrometer. The average diameter was calculated from two perpendicular diameter
measurements made to the nearest 50 µm. Each spheroid was individually transferred
into a well to be incubated with macrophages.
Following 48 hr of incubation, macrophages were transferred into 15-ml centrifuge
tubes and centrifuged at 600 rpm for 7 min. The resultant cell pellet was washed two
times with phosphate-buffered saline (PBS) while centrifuging and discarding the
supernatant in between washes. After suspending in DMEM and counting, 40000
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P388D1 macrophages were added per C-6 spheroid and 20000 NR8383 macrophages
were added per ACBT spheroid. The plate was incubated for 48 hr at 37°C in 5% CO2 to
allow the migration of macrophages and their infiltration of spheroids prior to irradiation.
For ACBT spheroids incubated with NR8383 macrophages, it was noticed that the
semi-adherent macrophages formed aggregates similar to spheroids. Consequently, the
solution in each well was pipetted several times the next day following co-incubation to
disperse the aggregates. Nanoshell-loaded macrophage aggregates were easily
distinguished from the spheroid by their acquired green color. However, empty
macrophage aggregates were indistinguishable from the spheroid, which necessitated
changing the control group to spheroids only (instead of spheroids incubated with empty
macrophages). Spheroids incubated with empty macrophages were used for imaging
macrophage migration and infiltration (see following section).
2.6.3 Imaging of Macrophage Migration and Infiltration of Spheroids
On the second day of incubation, plates were taken out of the incubator to obtain
images. Bright field images were acquired using a Photometries Cool Snap CCD camera
attached to a Nikon Eclipse TE2000-U microscope (Nikon Inc. Melvile, NY), while
colored images were acquired with a Canon PowerShot digital camera (Model S400).
2.6.4 NIR Laser Irradiation of Spheroids Infiltrated by Macrophages
On the day of laser therapy, spheroids were washed several times with PBS so as to
remove un-infiltrated macrophages. This was accomplished by transferring the spheroid
in between wells of a 96-well plate containing PBS. Then, the spheroid was transferred
into a well containing 200 µl DMEM to be irradiated.
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Groups are summarized in Table 1. 16 spheroids were used per group, and each group
treatment was repeated once. Two spheroid groups were irradiated: the laser control
group consisting of spheroids incubated with empty macrophages (for C-6) or spheroids
only (for ACBT), and the therapy group consisting of spheroids incubated with nanoshell
loaded macrophages.
Each spheroid was irradiated for 10 min with a 2-mm diameter laser spot at a
calibrated power of 1.75 W, producing a power density of ~ 55 W/cm2. Laser power was
monitored every 20-30 minutes to insure uniformity throughout the experiment.
Following irradiation, the spheroid was transferred into a well (containing 900 µl
DMEM) of a new coated 48-well plate for growth monitoring.
Spheroids were treated individually following the mentioned procedure, while
grouping every four spheroids into a single 96-well plate and incubating the plate for 30
minutes at 37°C in 5% CO2 to stabilize the medium’s temperature prior to irradiation.
The third spheroid group was a control i.e. it consisted of spheroids that were
incubated with nanoshell-loaded macrophages but were not subjected to any laser
treatment. Control spheroids were directly transferred to the 48-well plate for growth
monitoring following washing with PBS.
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Table 1. Groups for C-6 and ACBT spheroids.

2.6.5 Spheroid Growth Monitoring
Day 1 was set as the first day post-treatment when the initial average diameter was
measured, following which the average diameter was measured every 2-4 days for the
duration of 14 days. The medium was changed twice weekly by substituting 600 µl of the
old medium (usually containing multiplying macrophages) with fresh DMEM.
Due to spheroid loss during medium changing, the number of spheroids at the end of
the growth monitoring period was lower.
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2.7 Double-loading of Macrophages: Nanoshells and Ferumoxides
Double loading of macrophages with nanoshells and Ferumoxides was studied using
the UV-Vis-NIR spectrophotometer under two different conditions: simultaneous and
sequential incubation. The three groups were: macrophages simultaneously incubated
with nanoshells and Ferumoxides for 24 hr, macrophages incubated with nanoshells for
24 hr then with Ferumoxides for 24 hr, and macrophages incubated with Ferumoxides for
24 hr then with nanoshells for 24 hr.
5 x 106 P388D1 cells were used per group. 4.285 x 109 nanoshells (1 ml) and a
concentration of 100 µg Fe/ml for Ferumoxides were used. Following incubation at 37°C
in 5% CO2, macrophages were subjected to the same steps (centrifugation and washing)
followed for nanoshell-only incubations, and the absorbance of the resultant cellular
suspensions was measured at the 600-1100 nm wavelength spectrum. For groups
involving sequential incubation, macrophages incubated for 24 hr with the first
nanoparticle type were subjected to two washings with PBS before being transferred into
flasks and incubated with the second type.
For Ferumoxides, % decrease/increase in uptake due to the presence of nanoshells
was determined for each wavelength by:

where Δ is the difference in absorbance values of the doubly-loaded nanoparticles (AF+N)
and the endocytosed Ferumoxides of the Ferumoxide-loaded macrophages (AF). The
average % decrease/increase was then calculated for the 600-1100 nm spectrum. It should
be mentioned that such a computation can only be applied when the nanoshell absorbance
is negligible (~ zero), as was the case with simultaneous double-loading.
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2.8 Statistical Analysis
Microsoft Excel was employed for the calculation of the arithmetic mean, standard
deviation, and standard error in addition to plotting graphs. The effect of laser-activated
gold nanoshell therapy on spheroid growth was tested for statistical significance using
two-way analysis of variance (ANOVA) (SPSS version 17, Chicago, IL, USA).
Since two independent variables were involved: group (with three different groups or
levels: Control, Laser Control, and Therapy) and time (with seven time points or levels),
a 3x7 factorial ANOVA was performed for C-6 spheroids to observe if there was any
statistical interaction between group and time (group*time) at any combination of levels.
For ACBT spheroids, a 3x6 mixed factorial ANOVA was performed (six levels in time).
When no such interaction exists, the main effect (ME) of group and time would be
analyzed i.e. the effect of the variables (group) and (time) was examined separately. The
alpha level for significance for all analyses was set at 0.05.
The factorial ANOVA determines if the observed differences among the average
diameter sizes over time of different groups are greater than would be expected by chance
alone. It is based on the calculation of the F statistic, a ratio of inter-group variance to
intra-group variance. F is computed by:

where MSb is the inter-group mean square, and MSe is the error (intra-group) mean
square. When the treatment effect is significant, the inter-group variance is large, hence F
>1. The calculated F-ratio is then compared to a critical value to determine its
significance. It should be mentioned that a significant F-ratio (p < 0.05) is only indicative
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of a significant difference between at least two of the average diameter sizes. Multiple
comparison tests were then computed to determine exactly where the significant
difference was observed (Portney and Watkins 2009).
For ACBTs, and due to lower losses during washing, it was possible to keep track of
the growth of each individual spheroid over time (unlike C-6 spheroids which were
mixed up during repeated washings and were thus randomly measured). Consequently, a
mixed factorial ANOVA was conducted. When a statistical interaction between group
and time was observed, simple main effects (SME) were analyzed in order to breakdown
the interaction. SME consisted of nine tests: six different one-way ANOVAs that
compared the three groups at each of the six time points, and three repeated measures
ANOVAs that analyzed the average diameter size of each group independently over time.
Theoretically, these tests should be performed using a Bonferroni adjusted alpha (α =
0.0055) as the acceptable error cut off for significance, which is obtained by dividing the
original value of alpha (0.05) by the number of SME tests conducted (9). However,
because this was a pilot study, we chose to be liberal and to avert the Bonferroni
correction i.e. alpha < 0.05.
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CHAPTER 3
RESULTS
3.1 Ferumoxides Can Be Visualized Clearly ex vivo Using MRI
The signal drop along the Ferumoxide injection tract is clearly visualized on the T2*weighted MR images, as depicted in Fig. 19 (arrow). The hypointense area could be
detected for at least 30 minutes post-injection.

Figure 19. Visualization of the Ferumoxide injection tract (arrow). T2*-weighted gradient
echo MR image taken on a paraformaldehyde-fixed excised rat brain following the
injection of 0.2 ml of Feridex®.

3.2 Uptake of Ferumoxides in Macrophages is Dose-Dependent
Figure 20 depicts the calibration curve produced following the measurement of a
series of Iron Standards at ë = 238.2 nm, with an acceptable correlation coefficient r =
0.998. Samples were run and compared to the iron calibration curve for concentration
determination.
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Figure 20. The calibration curve for ICP-AES measurements of Ferumoxide. Six Iron
Standards with concentrations 0-25 ppm were run at ë = 238.2 nm. Each point denotes
three replicate measurements.

Figure 21 shows a dose-dependent response of murine (P388D1) and rat (NR8383)
macrophages respectively to increasing concentrations of Ferumoxides. It is also noticed
that the amount of Ferumoxide endocytosed in rat macrophages is much higher than that
in murine macrophages, as is denoted by the much higher intracellular iron measured
(over 50 fold at 400 µg/ml). One explanation for this observation is that rat macrophages
generally have a higher endocytotic capacity. Higher Ferumoxide concentrations were
not attempted due to cell toxicity already observed at 400 µg/ml. An optimal
concentration of 100 µg/ml was chosen for later experiments.
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Figure 21. Dose-dependent internalization of Ferumoxide in murine (A) and rat (B)
macrophages. Macrophages were incubated with Ferumoxide for 24 hr, and iron uptake
was assessed by ICP-AES. Each point represents the mean of 4 experiments. Error bars
(within points) denote standard deviations.
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3.3 Macrophages Are Highly Sensitive to NIR Laser Irradiation
The calibration curve of the MTS assay for murine macrophages is shown in Fig. 22.
Acceptable correlation (R2 = 0.9908) was produced. The curve was intended as an
indicator of proper performance of the plate reader and was not employed in viability
calculations.

Figure 22. The calibration curve for the MTS assay of murine macrophages. Each point
represents the mean of 4 wells. Wells were incubated with MTS/PMZ for 4 hr.
Absorbance was then read at 490 nm.

NIR irradiation of murine macrophages resulted in a significant decrease in survival
in a dose-dependent manner, as shown in Fig. 23.
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Figure 23. Response of murine macrophages to NIR laser irradiation. Each point
represents the mean of 4 wells. Five thousand macrophages per well were irradiated at λ
= 805.5 nm for 1 or 3 min. Percent survival was assessed 24 hr post-irradiation using the
MTS assay. Error bars denote standard error.

3.4 Nanoshells Are Endocytosed Into Vacuoles Dispersed Throughout The Cytoplasm
Bright Field TEM images of murine macrophages incubated for 24 hr with nanoshells
reveal extensive intracellular presence of the nanoparticles (Fig. 24). Nanoshells are
endocytosed into vacuoles which are dispersed throughout the cellular cytoplasm.
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A

B

Figure 24. Bright field TEM images of nanoshell-loaded murine macrophages. The
nanoshells are aggregated in vacuoles dispersed throughout the cytoplasm (A and B).
Magnification of a vacuole in A shows the high contrast nanoshells.
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3.5 Both Macrophage Cell Lines Show Significant Uptake of Bare Nanoshells
The bare and PEGylated nanoshell solution absorption curves supplied by
Nanospectra Biosciences are shown in Figure 25. Bare and PEGylated nanoshells have
maximum absorption at 819 nm and 795 nm, respectively.
Following incubation of the macrophages with the nanoshells for 24 hr, both murine
and rat macrophages showed uptake of bare nanoshells as measured by UV/Vis
spectrophotometry at λ= 819 nm. For P388D1 macrophages, uptake reached 15.74 %
(Fig. 26), which corresponds to 6.83 x 108 particles per 5 million macrophages suggesting
an average uptake of approximately 137 nanoparticles per macrophage. When uptake was
simulated from the reference nanoshell curve, absorbance values of the simulated and the
observed curves overlapped at the region of interest i.e. around 819 nm, indicating good
correlation.
For NR8383 macrophages, uptake was 8.26% (Fig.27), and the simulated curve
overlapped with the observed curve for most of the wavelength spectrum, including the
region of interest. % uptake corresponds to 3.615 x 108 particles per 1 million
macrophages suggesting an average uptake of approximately 362 nanoparticles per
macrophage.
Since 5 million cells were used for P388D1 macrophages versus only 1 million for
NR8383 macrophages, the number of nanoshells endocytosed by rat macrophages is
roughly 2.65 times that of murine macrophages, and is in reality even higher because cell
multiplication over the 24-hr incubation period was not accounted for: murine
macrophages have a much higher cell division rate resulting in an even lower number of
nanoparticles taken up per cell.
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A

B

Figure 25. Absorbance curves of bare (A) and PEGylated (B) nanoshell solutions as
supplied by the manufacturer. The solutions were labeled to have an optical density
(O.D.) of 1.6 at λ = 819 nm for bare nanoshells (no dilution) and 1.22 at λ = 795 nm for
PEGylated nanoshells (100x dilution).
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A
AN = 0.54

λ = 819 nm

AM+N = 0.085

B

Figure 26. Uptake of bare nanoshells by murine macrophages. Absorbances plotted are
corrected for respective backgrounds of solutions measured. Absorbances at λ = 819 nm
are shown in A. Uptake calculated from A (15.74%) was simulated in B (dotted line).
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A
AN = 0.54

λ = 819 nm

AM+N = 0.045

B

Figure 27. Uptake of bare nanoshells by rat macrophages. Absorbances plotted are
corrected for respective backgrounds of solutions measured. Absorbances at λ = 819 nm
are shown in A. Uptake calculated from A (8.26%) was simulated in B (dotted line).
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3.6 Murine Macrophages Endocytosed More PEGylated Than Bare Nanoshells
The % uptake of PEGylated nanoshells in murine macrophages was lower (3.96%)
than that of bare nanoshells (15.74%) (Fig. 28). However, the PEGylated nanoshell
solution was much more concentrated, and reasonable comparison should therefore be
between the respective numbers of nanoshells endocytosed by the macrophages (5
million in both groups). Murine macrophages endocytosed 59.63 x 108 PEGylated
nanoshells versus only 6.83 x 108 bare nanoshells. In other words, the total amount of
PEGylated nanoshells taken up by macrophages was 8.7 times that of bare nanoshells.

3.7 Macrophages Infiltrated The Spheroids
Bright field and colored images were taken of spheroids following 24 hours of
incubation with macrophages to observe macrophage infiltration of the spheroids. Figure
29 shows C-6 spheroids surrounded by murine macrophages. Nanoshell-loaded P388D1
macrophages did not display the characteristic green color of their load and could
therefore not be spotted inside the spheroids on color images (A), nor did the
endocytosed nanoshells provide sufficient dark contrast for identification on bright field
images (B and C).
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A
AN = 1.42

λ = 795 nm

AM+N = 0.562

B

Figure 28. Uptake of PEGylated nanoshells by murine macrophages. Absorbances plotted
are corrected for respective backgrounds of solutions measured. Absorbances at λ = 795
nm are shown in A. Uptake calculated from A (3.96%) was simulated in B (dotted line).
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A

B

C

Figure 29. Co-incubation of P388D1 macrophages and C-6 spheroids. A. Colored image
showing spheroid surrounded by macrophages, which are better distinguished on bright
field (BF) (B) and contrast modified BF (C) images. No differences could be detected
between spheroids incubated with empty or nanoshell-loaded macrophages.

Figure 30 shows ACBT spheroids surrounded by rat macrophages. Nanoshell-loaded
rat macrophages were easily distinguished by their acquired dark green color. Because
they are semi-adherent cells, their incubation in agarose-coated wells that prevent
spheroid adhesion caused their aggregation into clumps.
Macrophage infiltration of spheroids was visually detected on color images (Fig. 30
A) as well as on bright field images (Fig. 30 C and E) due to the dark contrast provided
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by the endocytosed nanoshells, contrary to spheroids incubated with empty macrophages
(Fig. 30 B, D and F).

Figure 30. Co-incubation of NR8383 macrophages and ACBT spheroids. Both images
show the nanoshell-loaded macrophages (dark green) attached to the spheroid (arrows).
Notice that macrophages are aggregated into clumps.
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A

B

C

D

E

F

Figure 31. ACBT spheroids infiltrated by rat macrophages. A and B are color images of
a spheroid infiltrated with nanoshell-loaded macrophages (dark green) (A) and another
spheroid infiltrated by empty macrophages (B). C is a bright field (BF) image and E is a
contrast-modified version of C, showing the same spheroid in A (nanoshells inside the
macrophages provided the contrast). D and F are BF and contrast-modified BF images of
a spheroid similar to B (macrophages cannot be distinguished from spheroid cells).
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3.8 Laser-Activated Nanoshell Therapy Delayed Spheroid Growth In ACBTs Only
The average spheroid diameters (µm) measured for each group of C-6 spheroids over
the period of 14 days post-irradiation are shown in Table 2 and plotted in Figure 32 A.
The interaction observed between group and time was not statistically significant, F(12,
347) = 0.56, p = 0.874, power = 0.324. However, the main effect of group was
statistically significant, F(2, 347) = 3.236, p = 0.041. Pair wise comparisons revealed that
while there was no statistically significant difference between Control and Therapy (p =
1) and Laser Control and Therapy (p = 0.39), the difference between Control and Laser
Control was statistically significant (p = 0.038).
The average diameter size was also affected by time, F(6, 347) = 5.259, p < 0.0005,
with pair wise comparisons showing statistical significance between Day 14 and the other
five time points (ps < 0.0005 for Days 1 and 6, and p = 0.036, 0.002, 0.016 and 0.001 for
Days 4, 7, 8 and 12, respectively).

Table 2. Descriptive statistics for C-6 Spheroids.
Average

Standard

Number of

Diameter

Deviation

Spheroids

Size (µm)

(µm)

(N)

1

293.75

39.656

32

4

296.88

52.341

16

6

263.33

38.807

15

7

275.00

44.320

15

8

291.07

41.146

14

Time
Group
(Days)

Control

87

12

286.11

68.718

18

14

321.15

98.344

13

Total

289.63

56.169

123

1

300.00

42.328

31

4

318.33

74.082

15

6

285.94

43.750

16

7

303.33

67.392

15

8

311.67

41.043

15

12

297.22

51.109

27

14

336.67

63.994

15

Total

305.6

54.724

134

1

282.76

34.785

29

4

288.24

38.647

17

6

267.50

45.720

10

7

295.00

51.927

15

8

285.00

66.875

10

12

295.00

69.111

20

14

360.00

92.946

10

Total

293.24

58.673

111

Laser Control

Therapy
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The average spheroid diameters (µm) measured for each group of ACBT spheroids
over the period of 14 days post-irradiation are shown in Table 3 and plotted in Figure 32
B. The interaction observed between group and time was statistically significant, F(10,
435) = 2.758, p = 0.046.
One-way ANOVAs (performed to study inter-group variability) revealed that there
was a statistically significant difference between Laser Control and Therapy on Days 12
(p = 0.039) and 14 (p = 0.028).
Repeated measures ANOVAs (performed to study intra-group variability) showed
that for the Control group, average diameter size differences were not statistically
significant (p = 0.142), but the difference in average diameter size between Day 12 and
14 was statistically significant (p = 0.032). For the Laser Control group, average diameter
size differences were statistically significant (ps < 0.0005), especially from Day 10 to
Day 14, suggesting a surge in spheroid growth. For the Therapy group, no statistically
significant differences were detected for the average diameter size over time (p = 0.338),
suggesting an arrest in spheroid growth.

Table 3. Descriptive statistics for ACBT Spheroids.
Average

Standard

Number of

Diameter

Deviation

Spheroids

Size (µm)

(µm)

(N)

Laser

261.21

44.111

29

Control

259.37

32.223

32

Therapy

255.17

41.393

29

Time
Group
(Days)

Day 1

89

Total

258.61

38.976

90

Laser

265.52

56.067

29

Control

259.37

32.223

32

Therapy

255.17

48.357
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Figure 32. Effect of laser-activated nanoshell therapy on (A) C-6 and (B) ACBT tumor
spheroid growth. Average spheroid diameter size (µm) was measured for 14 days postirradiation. 16 spheroids were used per group, and each group treatment was repeated
once. Error bars denote standard error.
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3.9 Macrophages Cannot Be Double-Loaded Simultaneously Or Sequentially
Figure 33 shows absorbance measured for the simultaneously double-loaded murine
macrophage solution. The curve shows preferential uptake of Ferumoxides over gold
nanoshells. No nanoshells were detected, as depicted by negative absorbance values
obtained when the absorbance of the Ferumoxide-loaded macrophages was subtracted
from that of the double-loaded macrophages over the entire spectrum.
The lower absorbance values of the double-loaded macrophage solution in
comparison to the Ferumoxide-loaded macrophage solution indicates decreased uptake of
Ferumoxides due to the presence of nanoshells. The average loss was 27.1% over the
600-1100 nm wavelength spectrum.

Figure 33. Simultaneous loading of gold nanoshells and Ferumoxides in murine
macrophages. Absorbances are corrected for respective backgrounds of solutions
measured. No nanoshells were detected, and Ferumoxides taken up were 27.1 % less than
those taken up by macrophages incubated with Ferumoxides only.
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When sequential loading of the two nanoparticles was attempted, neither nanoshells
nor Ferumoxides were detected in either group of P388D1 macrophages (Ferumoxide
loading following by nanoshell loading and vice-versa), as depicted by the negative
absorbance values for the two solutions (Fig. 34).

Figure 34. Sequential loading of gold nanoshells and Ferumoxides in murine
macrophages. Absorbances plotted are corrected for respective backgrounds of solutions
measured. Neither nanoshells nor Ferumoxides were detected in either incubation
protocol.

Following the 48-hr incubation with the two nanoparticles and double washing of the
macrophages, the resultant macrophage pellets showed coloration characteristic of the
second nanoparticle added (green for nanoshells and brown for Ferumoxides), indicating
uptake. Negative absorbance values obtained suggest therefore that the number of
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endocytosed nanoparticles was below the detection limit of the spectrophotometer rather
than the absence of uptake.
The spectrophotometer’s detection limit is 1% of the maximum absorbance value of
the reference nanoshell solution, which corresponds to 4.34 x 107 nanoshells. When
compared to the 6.83 x 108 particles taken up by macrophages incubated with nanoshells
only, it can be deduced that sequentially-loaded macrophages engulfed less than 6.35% of
nanoshells taken up by nanoshell-only loaded macrophages.
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CHAPTER 4
DISCUSSION

The clinical use of Ferumoxides for the acquisition of T2*-weighted images is well
documented (Neumaier et al. 2008). Rather than observing agar suspensions of the
Ferumoxides with MRI, the particles were visualized in an ex vivo model that is a more
accurate representation of the in vivo situation. As expected, deposited Ferumoxides
lowered the measured spin-spin relaxation time (T2*) through local field inhomogeneities
induced in nearby water molecules (Rogers et al. 2006), producing negative enhancement
along the injection tract.
ICP-AES quantitative analysis showed that Ferumoxides were incorporated by both
murine and rat macrophages in a dose-dependent manner, in agreement with other
published results involving SPIO and animal/human macrophages (Raynal et al. 2004;
Metz et al. 2004). Several researchers have studied macrophage labeling with SPIO, and
have so far shown that uptake is dependent on the cell and nanoparticle involved, in
addition to experimental conditions such as SPIO concentration and incubation duration
(Engberink et al. 2008; Hsiao et al. 2008). Variation in the intracellular iron content is
thus expected, and our results show that high intracellular iron content was achieved for
rat NR8383 macrophages at 100 µg/ml (43.56 pg/cell) versus only 0.76 pg/cell for
murine P388D1 macrophages.
Siglienti et al. (2006) were able to obtain 4.33 pg Fe/cell following the incubation of
rat peritoneal macrophages with 2 µM (112 µg Fe/ml) ferucarbotran (carboxydextrancoated SPIO) for 2 hr. Even though ferucarbotran has in principle a higher cellular uptake
due to its ionic surface coating (Metz et al. 2004), our results were much higher, possibly
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because of the longer incubation time (24 vs. 2 hr). On the other hand, Valable et al.
(2008) were able to obtain 2.8 pg/cell following the incubation of murine P388D1
macrophages with 62.8 µg Fe/ml MPIO (micrometer-sized particles of iron-oxide) for 18
hr. Earlier reports have proven that larger-sized iron oxide particles are more efficiently
phagocytosed (Metz et al. 2004), which explains why Valable et al. obtained a higher
intracellular iron content for their 0.9-μm particles compared to our 58.5-nm
Ferumoxides (Varallyay et al. 2002).
Rat macrophages displayed much higher intracellular iron content than murine
macrophages. This is likely due to the higher endocytotic capacity of rat macrophages
(Hrabak et al. 2008).
The irradiation of murine macrophages to increasing laser power densities resulted in
a dose-dependent decrease in survival, as assessed by the colorimetric MTS/PMZ
technique. At the maximum laser power density used (10 W/cm2) and for an irradiation
of 1 min, macrophage survival was 33% 24-hr post-irradiation. Tong and Cheng (2009)
have recently reported that mouse peritoneal macrophages irradiated at 2.18 W/cm2 for 15
min had a survival of 90.6%, as assessed by the colorimetric MTT technique immediately
after irradiation. However, direct comparison with the present findings is difficult since
the authors used a femtosecond (fs) Ti: sapphire laser emitting pulses with a 130-fs width
and a repetition rate of 80 MHz.
On the other hand, Berki et al. (1988) have found that the irradiation of mouse
peritoneal macrophages with a low-power, continuous-wave laser source at 60 J/cm2
results in less than 10% survival, as measured immediately after irradiation and 24 h later
by the trypan blue exclusion test. In comparison, the higher laser energy used in this
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study (600 J/cm2) produced higher survival (33%) while, for the same energy fluence (60
J/cm2), 63% survival was noted.
The discrepancy may be due to differences in macrophage cell densities. Berki et al.
irradiated 105 macrophages/well compared to 5000 macrophages/well in this study (both
in the same volume). It is possible that the higher cell density allowed thermal diffusion
between closely packed cells, resulting in more efficient absorption of laser energy
(Terentyuk et al. 2009), in contrast to energy dissipation and loss in the relatively dilute
cell suspension used in the present work.
The survival results of macrophage irradiation indicate that macrophages, as
nanoparticle vehicles, can be thermally ablated very easily at relatively low laser
densities and even in the absence of laser-activated nanoshells. Bernardi et al. (2008)
have shown that glioma cells require much higher laser power densities for photoablation
with nanoparticles. They used an output of 80 W/cm2 for 2 min from an 800-nm NIR
laser. Consequently, it is expected that using such a high laser output for nanoshell
activation will result in immediate ablation of the nanoshell-loaded macrophages and the
release of their cargo of laser-activated nanoshells into glioma cells. In other words, the
use of macrophages as vehicles is not expected to hinder the function of loaded
nanoshells as tumor-ablating tools.
TEM images taken of P388D1 macrophages incubated for 24 hr with gold
nanoshells are in agreement with images published by other groups (Choi et al. 2007b;
Tong and Cheng 2009), where phagocytosed nanoshells are seen in vacuoles dispersed in
the cytoplasm.
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In order to quantify the amount of gold nanoshells endocytosed by the macrophages,
nanoshell-loaded murine and rat macrophage suspensions were examined by UV/Vis
spectrophotometry over a wavelength spectrum overlapping with the nanoshell’s broad
absorption peak (600-1100). This technique has been employed by Kah et al. (2009) for
the same purpose, with an additional step of lysing the macrophages to release their
intracellular load of PEGylated nanoshells prior to measuring their absorption intensity.
On the other hand, Wang et al. (2009) followed a similar scheme as that used in the
present work: they studied the absorption peak of internalized gold nanoparticles (without
inducing cell lysis) and compared it to that of a reference nanoparticle suspension.
Murine macrophages showed 15.74 % uptake of bare nanoshells (6.83 x 108 particles
per 5 million cells), while rat macrophages had 8.26% uptake (3.615 x 108 particles per 1
million cells). As with Ferumoxides, rat macrophages displayed a higher uptake (roughly
362 particles/cell versus 137 particles/cell) that may be due to their higher endocytotic
capacity as discussed previously.
For both macrophage cell lines, it was noticed that the absorption peak is broader than
that of the reference nanoshell solution. In order to exclude the effect of different
nanoshell concentrations, a better comparison is with the simulated curve, which shows
that peak broadening results in incomplete overlap of the curves (more visible with
murine macrophages). Similar results have been reported by Wang et al. (2009), and were
considered an indication of the aggregation of the nanoshells within the macrophages.
TEM images may further support this through the vesicular grouping seen of endocytosed
nanoshells.
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Choi et al. (2007b) have observed more subtle defects in internalized nanoshell
morphology which, however, were not expected to destroy their resonant optical
absorption properties. Because the peaks of the curves do overlap at the region of interest
i.e. at the surface plasmon resonance wavelength of the nanoshell where the highest
absorption occurs, it can be safely deduced that nanoshell aggregation within the cells is
not expected to affect their functioning as laser light absorbers.
The addition of the PEG polymeric coating to the surface of nanoparticles was
employed to reduce macrophage recognition of the particles, thus prolonging their
circulation time (Kah et al. 2009). However, their uptake by macrophages is not
completely inhibited, as is seen from various studies involving PEGylated nanoparticles
and macrophages (Huang Y et al. 2009; Tong and Cheng 2009; Wang et al. 2009).
Additionally, PEG provides gold nanoshells with a hydrophilic surface that improves
their stability in aqueous media by providing a steric barrier between interacting particles.
Commercially, this implies that stable, highly concentrated suspensions of PEGylated
nanoshells can be prepared, unlike bare nanoshell suspensions that cannot be prepared as
concentrated due to aggregation problems (Kah et al. 2009).
Incubation of macrophages with a concentrated suspension of PEGylated nanoshells
was performed in order to verify that PEGylated nanoshells can be endocytosed by
macrophages. The PEGylated nanoshells used in the present work were coated with PEG
chains of ~ 4700 Da in length. Kah et al. (2009) have shown that moderate chain length
(between 2000 to 5000 Da) gives the lowest macrophage uptake. However, it has also
been shown previously that increasing the concentration of PEGylated nanoshells can
promote higher uptake rates in macrophages (Zahr et al. 2006). Not surprisingly, the
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UV/Vis spectrophotometry studies showed that macrophages were able to uptake more
PEGylated nanoshells than bare nanoshells (8.7 times), due to the much higher
concentration of PEGylated nanoshells.
Wang et al. (2009) were able to achieve 18200 PEGylated gold nanoparticles per cell
when they incubated mouse monocyte-macrophage (J774A.1) cells with a suspension of
PEGylated nanoparticles (~ 4 × 1010 particles/ml) overnight. In the present study, roughly
1193 particles per cell were detected following incubation in a suspension of PEGylated
nanoparticles (~ 3 × 1010 particles/ml) for 24 hr.
The authors used a higher nanoparticle concentration and did not specify the initial
number of macrophages incubated, which can lead to increased uptake if the number of
cells added was lower. Additionally, they counted the number of macrophages on the day
of measurement, whereas our calculations were based on the number of macrophages
added for incubation 24 hr earlier, thus not accounting for cell multiplication during the
incubation period and/or losses during washing.
Possibly the most influential factor is the fact that the authors measured the
absorbance of the incubating medium before and after incubation to determine the
number of particles internalized by cells, rather than measuring the absorbance of the
nanoparticles within the cells. This approach can result in positive error due to medium
losses during the process of aspiration and separation from the cell pellet (following
centrifugation), thus resulting in a greater difference in absorbance values of the medium
(before and after incubation) that could be attributed to a greater number of nanoparticles
taken up. On the other hand, the approach used herein can result in negative error due to
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the loss of cells during washing, thus resulting in a smaller absorbance value that would
be attributed to a lower number of nanoparticles taken up.
After establishing the loading of macrophages, experiments were initiated to
determine the ability of macrophages to infiltrate tumor spheroids. The infiltration of
ACBT spheroids by rat macrophages observed in both colored and bright field images is
in agreement with results published by Choi et al. (2007b). Using H and E staining, they
showed that human macrophages accumulate within the hypoxic rim and around the
central necrosis of human T47D breast tumor spheroids. For C-6 spheroids, the small size
of the murine macrophages and their lower nanoparticle load prevented them from being
distinguished within spheroids in both types of images.
Choi et al. (2007b) were the first to study macrophages as gold nanoshell vehicles or
“Trojan Horses” for photothermal ablation of tumors. They studied the effect of laser
irradiation on spheroids infiltrated with loaded macrophages by taking fluorescent images
immediately after irradiation, which showed dead spheroid cells within the irradiated
area. However, they did not follow up on spheroid growth following irradiation, which
greatly limits the scope of their results. Many aggressive cancer therapies can induce
instantaneous damage; however, the efficiency of therapy relies on its ability to hinder
tumor growth and/or eradicate it with time. Therefore, in the present study, spheroid
growth was followed for 14 days post-irradiation.
C-6 spheroids did not respond to laser activated-nanoshell therapy, which suggests
that either the number of gold nanoshells migrating into the spheroid or the laser energy
fluence was suboptimal. Compared to the control groups, no statistically significant
growth delay was observed in the treatment group over the 14 day observation period. Of

101

particular interest is the observation that laser-treated spheroids (Laser Control) exhibited
greater growth than non-irradiated controls. The reason for this is not known but may be
related to the observation that gliomas express higher levels of heat shock protein 90
(HSP 90) than normal tissues and, as such, cells surviving thermal stress (reversible
damage) are associated with resistance and with tumor recurrence due to apoptosis
inhibition exerted by HSP 90 (Everts 2007, Ohba et al. 2010).
Increasing the number of nanoshells migrating into the spheroid can be accomplished
by increasing the nanoshell uptake of the macrophages, such as using PEGylated
nanoshells which were shown to have higher uptake. Increasing the number of
macrophages is another option, though it is not expected to be significant, since only a
fixed number of macrophages penetrated the spheroids.
Spheroids were irradiated with a laser power density of ~ 55 W/cm2 for 10 min,
which is equivalent to an energy fluence of 33000 J/cm2. In comparison with tumor
monolayer irradiation, this energy fluence is extremely high. For example, Bernardi et al.
(2008) used a laser power density of 80 W/cm2 for 2 min (energy fluence of 9600 J/cm2)
to activate gold nanoshells added to glioma (U373 and U87) monolayers. However, it is
important to note that efficacy can be achieved in monolayers at lower laser fluences than
multilayered spheroids that harbor hypoxic, resistant cells at their core.
Since the primary purpose of the in vitro data is to establish guidelines for in vivo
applications, perhaps a better approach for increasing efficacy would be to increase the
load of macrophages by incubating them with PEGylated nanoshells instead of increasing
the laser power density, since the latter requires longer irradiation times which may be
difficult to achieve in in vivo studies.
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In contrast to C6 spheroids, a significant response was noted for ACBT spheroids
treated with laser-activated nanoshells. Compared to the laser-only irradiated control
group, a significant growth delay was observed in the therapy group beginning on Day 10
following irradiation.
When observing within-group variability, Laser Control spheroids displayed a surge
in tumor growth, particularly after Day 10. For ACBT spheroids, this group was
represented by spheroids not incubated with any macrophages, which may possibly
indicate that the intraspheroidal presence of the macrophages is hindering the spheroidal
normal growth rate.
Finally, the attempt of double-loading the macrophages with Ferumoxides and gold
nanoshells failed in both modes: simultaneous and sequential incubation. For
simultaneous incubation, murine macrophages showed preference for Ferumoxides over
nanoshells, but even Ferumoxide uptake was ~ 27% lower in the presence of the
nanoshells.
The uptake of nanoparticles by macrophages is mainly governed by surface charge
and size (Rogers et al. 2006; Zahr et al. 2006), whereby a negative surface charge and a
large size are preferred over a neutral surface and a small size, respectively.
Nanoshells have a particle diameter of ~150 nm, while Ferumoxides have a mean
particle diameter of 58.5 nm. Therefore, it is expected that macrophages would prefer the
larger-sized nanoshells. However, Ferumoxides’ hydrodynamic diameter has a broad
range of 80–150 nm that would be expected to affect the rate of macrophage uptake
(Metz et al. 2004; Rogers and Basu 2005). Additionally, it has been reported that
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colloidal Ferumoxide particles in solution can be much larger than their dry size due to
the hydrated dextran surface layer (Jung and Jacobs 1995).
Upon comparing their surface charge, both nanoparticles are within comparable
ranges. Gold nanoshells have a significant negative surface charge (reaching - 30-40
mV) arising from the cloud of loose electrons (Kah et al. 2009), in addition to adsorbed
carbonate ions from the gold deposition process. On the other hand, the dextran surface
coating of Ferumoxides renders them highly negatively charged (Arbab et al. 2004; Jing
et al. 2008; Omidkhoda et al. 2007). A Ferumoxide solution of 100 µg Fe/mL
concentration (the same as that used for simultaneous incubation) has a zeta potential of 32.24 mV (Arbab et al. 2004).
Since surface charge is comparable for the two nanoparticles, it seems that preference
for Ferumoxides is likely a result of their larger size due to their hydrated dextran
coating. A second possible reason can be that Ferumoxides have been shown to have a
higher uptake by J774A.1 murine macrophages when incubated in DMEM including 10%
FBS compared to cells in which FBS was withheld (Rogers and Basu 2005). This is
because FBS (fetal bovine serum) adsorbs on the particle surface, acting as an opsonin
that facilitates macrophage recognition and uptake. Since our culture medium was
supplemented with 10% FBS, this may be an additional factor favoring their uptake. No
studies have specifically targeted the effect of FBS presence on nanoshell uptake, though
their opsonization by serum blood proteins has been reported (Hirsch et al. 2006;
Terentyuk et al. 2009).
The lower uptake of Ferumoxides, in the presence of nanoshells, can be due to
competition between the two particles. Even though no gold nanoshells were detected by
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spectrophotometry, this does not necessarily indicate their absence, but may be due to
their extremely low concentration. In other words, Ferumoxides were favorably but not
solely endocytosed, ultimately resulting in a decreased uptake when compared to that of
macrophages incubated with Ferumoxides only.
Consecutive loading of macrophages also failed. In principle, it was expected that the
second nanoparticle added would have lower or no uptake, since macrophages may
already be saturated with the first nanoparticle. However, the inability to detect the first
nanoparticle was unexpected since their macrophage uptake has already been shown.
In the Ferumoxide-first case, this anomalous observation may be partly explained by
a study of Arbab et al. (2003), which shows that Ferumoxides taken up by rapidly
dividing HeLa cells (doubling time of 2.6 days) disappeared completely by the 5th to 8th
generation, which was attributed to dilution following cellular division or metabolism.
Our murine macrophages have a much shorter doubling time (less than 8 hr), which could
therefore explain why Ferumoxides were no longer detectable by 48 hr. However, this
also indicates that even the diluted amount of Ferumoxides carried by daughter cells
hindered any further uptake of gold nanoshells.
On the other hand, the authors speculated that exocytosis might also have played a
major role in the release of iron from the cells. Whether exocytosis occurs and may have
been induced by nanoshells, and the reason for the lack of nanoshell uptake if
Ferumoxides were already exocytosed, needs further experimentation.
Failure to detect both nanoparticles is even harder to explain in the case of
nanoshells-first incubation, due to the scarcity of articles observing intracellular loading
of cells with gold nanoshells. However, it may similarly be assumed that the long
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incubation period led to dilution, and that the low nanoshell load “inherited” by daughter
cells was undetectable, yet sufficient to prevent any further uptake of Ferumoxides. In
this context, double-loading experiments in rat macrophages may provide valuable
information since these cells have a much lower division rate.
Though the attempt to double-load the macrophages did not prove successful, the
principle of tracking the nanoshell-loaded macrophages with Ferumoxide is still feasible
from a different approach i.e. separately loading macrophages with Ferumoxides, then
mixing Ferumoxide-loaded macrophages with nanoshell-loaded macrophages in a single
injection. Such an approach assumes that macrophages, though differently loaded, behave
similarly, so that MRI signals detecting the presence of Ferumoxide-loaded macrophages
can be considered as indicators of the presence of nanoshell-loaded macrophages.
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CHAPTER 5
CONCLUSION

It has been shown that both murine and rat macrophages can be separately loaded
with Ferumoxides and with gold nanoshells, and that loaded macrophages are capable of
migrating towards and of infiltrating glioma spheroids upon co-incubation.
Proof-of-principle of laser-activated nanoshell therapy has been demonstrated in
human glioma spheroids. The lack of a C-6 spheroid response was likely due to
insufficient uptake of nanoshells. Potential solutions include the use of PEGylated
nanoshell-loaded murine macrophages or of bare nanoshell-loaded rat macrophages (both
of which have shown higher nanoshell loading). Additionally, individual C-6 spheroid
growth tracking would permit the use of mixed factorial ANOVA that reduces data
variability and thus increases the power to detect effects.
The next step would be to examine nanoshell-loaded macrophages in an in vivo
setting, such as a rat glioma model. Though double-loading has failed, injections
containing a mixture of Ferumoxide-loaded and nanoshell-loaded macrophages are still
an option, and the next challenge lies in producing significant results in vivo using the
data obtained in this work as a guide.
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